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Ribonucleotide reductase catalyzes the rate-liming step in deoxyribonucleotide 
triphosphate biosynthesis and is a major determinant of genomic integrity. Unbalanced 
dNTP pools can cause genetic abnormality and cell death. Although a number of 
elaborate regulatory mechanisms govern RNR activity, the physiological impact of 
RNR deregulation had not previously been examined in an animal model. The aim of 
this dissertation is to elucidate the physiological effect of RNR deregulation using 
transgenic mouse models and to further dissect the molecular mechanisms of RNR-
induced mutagenesis and lung tumorigenesis. 
 
We generated transgenic mice that broadly overexpress individual RNR genes, 
and found that overexpression of the small RNR subunit potently and selectively 
induces lung neoplasms. RNR deregulation was found to promote lung carcinogenesis 
through a mutagenic mechanism, as evidenced by increased mutation rates in RNR 
overexpressing 3T3 cells and enhanced mutagenesis and carcinogenesis when 
combining RNR deregulation with defects in DNA mismatch repair. Moreover, the 
proto-oncogene K-ras was identified as a frequent mutational target in RNR-induced 
lung neoplasms. Importantly, RNR-induced lung neoplasms histopathologically 
resemble human papillary adenocarcinoma, making RNR transgenic mice a 
  
particularly authentic model for lung cancer. 
 
We initially hypothesized that RNR-induced mutagenesis and carcinogenesis 
was due to disturbed dNTP pools. However, we observed no alteration of dNTP levels 
or ratios in RNR overexpressing cells, suggesting that RNR-induced mutagenesis 
might be independent of RNR enzyme activity. Moreover, RNR overexpression was 
not associated with acute transforming activity. Alternatively, excess free radical 
production by the small RNR subunit may account for lung specific carcinogenesis in 
RNR transgenic mice. To further assess the requirements for free radical production 
and RNR enzyme activity in RNR-induced mutagenesis, we generated Rrm2 mutants 
and found that Rrm2 overexpressing cells exhibited significantly higher intracellular 
reactive oxygen species levels and Rrm2 mutants that are defective for RNR enzyme 
activity still promote mutagenesis in cultured 3T3 cells and exhibited elevated reactive 
oxygen species levels. Our data suggest that increased ROS production, rather than 
increased RNR enzyme activity, is the major driving force of RNR-induced 
mutagenesis, and potentially lung tumorigenesis.  
 
These studies establish a new oncogenic activity for the small subunit of RNR. 
RNR-induced lung tumors arose with moderate latency in a stochastic process 
associated with an elevated mutation rate and increased ROS production. This novel 
mouse lung cancer model holds great promise for providing insights into basic 
mechanisms in human lung cancer and developing effective strategy for prevention 
and therapy of lung cancer.  
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1 
CHAPTER 1 
 
Literature Review 
 
1.1    Deoxyribonucleotide triphosphates and genome integrity 
A balanced supply of deoxyribonucleotide triphosphates (dNTPs), the basic 
building block of DNA, is fundamental for ensuring DNA replication fidelity and 
efficient DNA damage repair. Imbalanced dNTP pools can cause genetic defects. 
Therefore, the control of dNTP concentrations is essential for the maintenance of 
genetic stability, and disruption of this control can cause the accumulation of 
mutations in oncogenes or tumor suppressor genes, resulting in tumorigenesis.  
 
1.1.1 dNTP biosynthesis pathways 
dNTPs are synthesized by two biosynthetic pathways, the de novo and the 
salvage pathway. In the de novo pathway, dNTPs are produced in multiple steps from 
the principle products of purine and pyrimidine, inosinic acid (IMP) and uridine 
monophosphate (UMP), respectively (Fig 1.1) (Kunz, 1988; Kunz et al., 1994). Except 
for dTTP, dNTPs are derived from the reduction of corresponding ribonucleoside 
diphosphates (NDPs) to deoxyribonucleoside diphosphates (dNDPs) by ribonucleotide 
reductase (RNR). The dNDPs are then phosphorylated to the triphosphates by 
nucleoside diphosphate kinase.  dTTP is produced from dUMP, which is generated 
either from hydrolysis of dUTP by dUTPase or from deamination of dCMP by the 
dCMP deaminase. Then dUMP is methylated by dTMP synthase to produce dTMP,  
with N5, N10-methylene tetrahydrofolate (MTHF) serving as a methyl donor. Finally, 
dTMP kinase phosphorylates dTMP to dTDP, which is in turn phosphorylated to 
dTTP by nucleoside diphosphate kinase. In the salvage pathway, dNTPs are generated 
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              Figure 1.1 The de novo dNTP biosynthesis pathway. 
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 in single steps from deoxyribonucleosides by deoxyribonucleoside kinases(Reichard, 
1988). Mammalian cells have two sets of deoxyribonucleoside kinases: one is present 
in the cytosol, and the other in mitochondria. The cytoplasmic and mitochondrial 
isozymes of thymidine kinase (TK) are called TK1 and TK2, respectively, which play 
import roles in dTTP salvage biosynthesis. Deoxycytidine kinase (dCK), in addition to 
phosphorylating deoxycytidine, also plays a dominant role in salvage synthesis of 
dAMP and dGMP. Adenosine and guanoside kinase (dAK and dGK), also 
phosphorylate the resepective deoxyribonucleosides, but relatively inefficiently (Kunz 
et al., 1994).  
 
1.1.2 Imbalanced dNTP pools and genomic instability 
Biosynthesis of dNTPs is precisely regulated with respect to concentration and 
timing (Kunz et al., 1994). Cell cycle dependent control of dNTP pools results in 
periodic but coordinated changes in dNTP pool size during the cell cycle. In S phase 
dNTP levels are elevated to coinciding with DNA replication. In contrast, dNTP 
concentration is maintained at low levels for DNA repair and mitochondrial DNA 
replication in G1/G0, and G2/M phases. In addition to cell cycle control, the control of 
dNTP pool sizes is also linked to DNA damage responses (Mathews, 2006). 
Loss of normal control of dNTP biosynthesis results in imbalances in dNTP 
pools and leads to aberrant DNA replication, enhanced mutagenesis, stimulated 
recombination, enhanced sensitivity to DNA damage reagents, oncogenic 
transformation and cell death(Kunz and Kohalmi, 1991; Mathews, 2006). Deficiency 
in all four dNTP pools or deprivation of any of dNTPs, such as dTTP deprivation, lead 
to incomplete DNA replication and defect in DNA repair, and cause mutagenesis and 
cell death (Reichard, 1988). Elevated dNTP pools, including unbalanced dNTP pool 
expansion with accumulation or depletion of one nucleotide and balanced expansion 
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of all four dNTP pools proportionally, are mutagenic (Kunz et al., 1994; Wheeler et 
al., 2005). 
The mechanisms of mutagenesis caused by imbalanced dNTP pools have been 
extensively explored. Excess or deficient dNTPs results in non-Watson-Crick base 
pair and mis-insertion during DNA replication.  In the presence of elevated nucleotide 
pools, the rate of base mis-insertion is increased during DNA replication and the 
efficiency of proof-reading is decreased due to the enhanced polymerization rate, 
termed “next-nucleotide effect”. Both dNTP mis-insertion and next-nucleotide effects 
contribute to the mutagenicity of dNTP imbalance in vivo (Kunz and Kohalmi, 1991). 
dNTPs in excess can also form a correct base pair at a slipped or dislocated 3’ 
terminus and lead to frameshift mutations (Bebenek et al., 1992). Furthermore, altered 
dNTP levels might influence the repair of damaged DNA (Kunz and Kohalmi, 1991). 
Hydroxyurea, an inhibitor of RNR, has been found to inhibit DNA-excision repair in 
human cells as a consequence of reduced dNTP levels (Snyder, 1984; Snyder, 1985). 
Finally, constitutively high dNTPs in inhibit cell cycle progression and leads to a 
defect in DNA damage checkpoint response (Chabes and Stillman, 2007). 
Mutagenic effect caused by imbalanced dNTP pool size has been suggested to 
contribute to the carcinogenesis. Thus, dNTP pool sizes have to be tightly controlled 
to prevent genomic instability and cancer development. Cells utilize multilevel 
controls to maintain the optimal dNTP level, which ensures the replication accuracy 
and genome stability. Among these controls, allosteric control and genetic control of 
the enzymes involved in dNTP biosynthesis are major mechanisms to maintain a 
balanced dNTP concentration and ratios.  
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1.2    Ribonucleotide Reductase (RNR) 
RNR catalyzes a crucial rate-limiting step of the de novo synthesis of dNTPs 
and is the sole enzyme responsible for reducing all four NDPs to the corresponding 
dNDPs, which are subsequently phosphorylated to dNTPs. Thus, RNR occupies a key 
position in the dNTP synthesis and plays an essential role in accurate DNA replication 
and repair by supplying adequate and balanced dNTPs for cells. RNR is indispensable 
for the survival of all living organisms.  The key role of RNR in DNA synthesis, and 
thereby cell proliferation, makes RNR an important target for cell growth control and 
target of chemotherapeutic treatment of cancer. 
1.2.1 RNR enzyme 
1.2.1.1    Classification of RNR 
There are three main classes of RNR enzymes that depend on different metal 
cofactors for catalytic activity (Kolberg et al., 2004). Class I enzymes contain an 
oxygen-bridged dinuclear iron center, class II enzymes contain cobalamin cofactor 
(vitamin B12), and class III enzymes contain an iron-sulfur cluster coupled to S-
adenosylmethionine (SAM). However, all three classes have a conserved cysteine 
residue at the active site that is converted to a thiyl radical, which initiates the 
substrate reduction by abstracting a hydrogen atom from the ribose ring of the 
substrate (Kolberg et al., 2004). The thiyl radical site is located on the tip of a protein 
loop in the center of a αβ barrel in all three classes of RNR. In the class II, the metal 
cofactor may interact directly with the active site cysteine, whereas in class I and class 
III, a stable protein radical is generated on a separate subunit and the radical is then 
transferred to the catalytic site through a radical transfer pathway consisting a chain of 
hydrogen bonded amino acid residues (Kolberg et al., 2004). All eukaryotic RNR 
enzymes belong to class I and are oxygen-dependent.  
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1.2.1.2    Overall structure of the RNR enzyme 
In mammals, RNR is composed of two non-identical homodimeric subunits, 
the large subunit R1 and the small subunit R2 (Fig. 1.2). The large subunit R1 exists 
as a homodimer with a molecular weight of 170 kD (Wright et al., 1990). Each R1 
monomer harbors a catalytic site, which reduces the substrate, and two allosteric 
regulation sites (specificity site and activity site, which will be discussed in detail 
later). Each R1 monomer is composed of three domains: one αβ barrel domain, an N 
terminal domain and one small domain (Uhlin and Eklund, 1994). The catalytic site is 
located in a cleft between the N-terminal domain and barrel domain. Two-monomer 
interaction area buries 4% of R1 surface area. 
The small subunit R2 is a homodimer with a molecular weight of 88 kD and 
forms a heart shape. Each R2 monomer contains an oxygen-bridged dinuclear iron 
center and a unique tyrosyl free radical, which is transferred through a radical transfer 
path to produce a thiyl radical in the catalytic site of R1 subunit. This tyrosyl free 
radical is situated in a hydrophobic environment close to the dinuclear iron center and 
is deeply buried inside the R2 subunit, protected from solvent.  The N-terminal of R2 
is not needed for enzyme activity, but is important for cell cycle regulation of the RNR 
enzyme. The C-terminal of R2 is important for the formation of the holoenzyme 
complex with R1 (Uhlin and Eklund, 1994) (Uppsten et al., 2006). The dimer appears 
to be a very stable entity. Two-monomer interaction area is extensive and buries 
18.5% of the accessible surface (Eklund et al., 2001). 
 
1.2.1.3    RNR catalytic mechanism 
At the catalytic site of the R1 subunit, a thiyl radical initiates catalysis by 
abstracting the 3’-hydrogen atom from the ribose ring of the substrate ribonucleotide  
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Figure 1.2  Schematic showing the structure of RNR and the reaction it catalyzes. 
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to generate a substrate radical (Uppsten et al., 2006). An essential redox cysteine pair 
at the catalytic site of R1 then reduces the substrate radical to deoxyribonucleotide by 
replacing the 2’-hydroxyl group on the ribose ring by a hydrogen atom. After reducing 
the substrate, a disulfide bond between the redox cysteine pair is formed and has to be 
reduced before the enzyme can be active again. Oxidized RNR can be reduced by the 
thioredoxin and glutaredoxin system. Oxidized thioredoxin and glutaredoxin then can 
be reduced by thioredoxin reductase and glutathione reductase, both depending on 
NADPH to provide final reducing power. Additional redox cysteine pair at the surface 
of the flexible C-terminus of R1 is involved in the reactivation of the enzyme by 
swinging out to the surface to be reduced and then swinging in again to the catalytic 
site to affect reduction (Eklund et al., 2001; Uhlin and Eklund, 1994).  
 
1.2.1.4    Radical formation and storage  
The thiyl radical that initiates the catalysis in the R1 subunit is transiently 
generated by a long-range radical transfer path from a stable tyrosyl radical in the R2 
subunit (Kolberg et al., 2004). The R2 subunit contains a dinuclear iron center and a 
stable tyrosyl radical, which is reduced and re-oxidized during each catalytic cycle 
(Uppsten et al., 2006).  
The dinuclear iron center in the R2 subunit possesses a strong oxidation power 
and is responsible for generating the stable tyrosyl radical. When oxygen reacts with 
the diferrous R2 (Fe(II)-Fe(II)), it will spontaneously oxidize the diiron center through 
a series of intermediate states, leading to a oxygen-bridged diferric iron cluster 
(Fe(III)-Fe(III)) and oxidizing the tyrosine residue (Y177 in mouse R2) to the tyrosyl 
radical (Uppsten et al., 2006).  
In mammals, formation of one dinuclear iron cluster in one R2 monomer can 
very strongly increase the formation of the second cluster in the second R2 monomer 
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(Kolberg et al., 2004). In addition, mammalian R2 has a low affinity to iron (II), which 
might be a novel regulatory mechanism utilized for preventing the formation of the 
tyrosyl radical when it is not needed, or under unfavorable growth conditions, such as 
hypoxia (Graff et al., 2002). The dinuclear iron center of mouse R2 are labile, and 
although the same mouse R2 dimer can carry out several redox cycles, a continuous 
supply of ferrous iron and oxygen is needed to keep the enzyme fully active (Kolberg 
et al., 2004). 
When the tyrosine 177 residue in the mouse R2 subunit is mutated for another 
redox-active amino acid with a suitable side chain and appropriate redox potential, like 
tryptophan (W), this residue can be oxidized. However, despite the formation of a 
transient tryptophan radical, no catalytic activity could be detected in the R2-Y177W 
mutant (Potsch et al., 1999). Moreover, when the tyrosine 177 is mutated to 
phenylalanine (F), cysteine (C), or histidine (H), all these mutants also lose enzyme 
activity, suggesting strongly that the tyrosyl radical 177 cannot be replaced by other 
amino acids (Potsch et al., 1999). 
 
1.2.1.5    Radical transfer 
The stable tyrosyl radical in the R2 subunit is transferred through a long-range 
proton-coupled radical transfer path to the thiyl radical at the catalytic site in the R1 
subunit. This radical transfer path consists of a chain of conserved hydrogen-bonded 
residues between the catalytic site of R1 and the tyrosyl radical of R2 (Nordlund and 
Reichard, 2006), which involves following conserved residues: His173, Asp266, 
Trp103 in the R2 subunit and Tyr738, Tyr737, Cys429 in the R1 subunit (Nordlund 
and Eklund, 1993; Uhlin and Eklund, 1994).  
In addition, a tyrosine residue (Y370 in mouse), localized in the flexible C-
terminus of the R2 subunit, has been found to link the radical transfer path in the R2 
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subunit to the radical transfer path in the R1 subunit during the radical transfer (Rova 
et al., 1999). Site-directed mutagenesis of this tyrosine residue to phenylalanine or 
tryptophan (Y370F and Y370W) has been found to inactivate RNR enzyme activity. 
The Y370F mutant protein was completely inactive, whereas the Y370W mutant 
protein only had 1.7% of the wildtype RNR enzyme activity (Rova et al., 1999). 
Although this tyrosine residue localizes to the C-terminus of the R2 subunit, it is not 
involved in the binding of the R1 subunit (Rova et al., 1999). 
 
1.2.2 RNR genes 
1.2.2.1    Mouse RNR genes 
The genes for the mouse R1 and R2 subunits are regulated separately and are 
located on separate chromosomes. Three RNR genes have been identified.  
The large subunit R1 is encoded by the Rrm1 gene, which consists of 19 exons and 
spans 26 Kb on chromosome 7; the small subunit R2 is encoded by the Rrm2 gene on 
chromosome 12 or the recently identified p53R2 gene on chromosome 15, which 
shares 80% homology with Rrm2 gene. Rrm2 gene is 5.9 Kb and consists of 10 exons, 
whereas p53R2 gene is 37 Kb and consists of 9 exons (Guittet et al., 2001; Jordan and 
Reichard, 1998). A heterotetrameric complex of Rrm2 and Rrm1 accounts for most 
RNR activity during S phase. p53R2 was originally identified as a target gene for the 
p53 tumor suppressor protein and is transcriptionally induced following DNA damage 
(Nakano et al., 2000; Tanaka et al., 2000). Mouse p53R2 displays 81% identity to 
mouse Rrm2 at the amino acid level, but lacks the KEN box required for Rrm2 
degradation in late mitosis. In addition to its role in stress responses, p53R2 is 
expressed at low levels throughout the cell cycle and complexes with Rrm1 to produce 
dNTPs for continuous mitochondrial DNA replication in quiescent cells (Bourdon et 
al., 2007; Hakansson et al., 2006b; Pontarin et al., 2007).  
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Several known functional domains in mouse Rrm2 are conserved in p53R2, 
including the iron center, tyrosine radical site, the hydrophobic pocket surrounding the 
tyrosyl radical site, the radical transfer pathway from the small subunit to the large 
subunit, and the hydrophobic channel from the surface to the interior of the protein. 
The major sequence difference between Rrm2 and p53R2 is that p53R2 lacks 33 
amino acid residues in its N-terminus (Chabes et al., 2004; Guittet et al., 2001). The 
tyrosyl radical signal in the p53R2 protein is almost identical with that in Rrm2 
protein. However, the reaction rate of p53R2 is lower than that of Rrm2, which may 
be due to its reduced binding affinity to R1(Shao et al., 2004).  
 
1.2.2.2    Yeast RNR genes 
Yeast contains four RNR genes. RNR1 and RNR3 encode the large subunit R1, 
and RNR2 and RNR4 encode the small subunit R2. RNR1 and RNR3 are two highly 
homologous genes (Elledge and Davis, 1990). The standard large subunit R1 in yeast 
is a RNR1 homodimer. RNR1 is essential for yeast. Levels of RNR1 mRNA fluctuate 
during the cell cycle, being the highest during S phase, while RNR3 mRNA is induced 
only after DNA damage, and is not essential. The small subunit of R2 in yeast is a 
heterodimer of RNR2 and RNR4, with RNR4 stabilizing an active RNR2-RNR4 
complex (Chabes et al., 2000; Eklund et al., 2001). 
 
1.2.3 Regulation of RNR 
Due to its vital importance to cellular physiology, RNR enzyme activity is 
tightly controlled by a variety of elaborate regulatory mechanisms:  allosteric 
regulation, cell cycle regulation, subcellular localization regulation, and small 
inhibitory protein regulation. 
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1.2.3.1    Allosteric regulation of RNR 
RNR has unique allosteric regulation mechanism through the large subunit R1 
because triphosphate nucleotides regulate the substrate specificity and overall enzyme 
activity in such a way that a balanced supply of the different deoxynucleotides are 
present during DNA synthesis but also the enzyme can adapt rapidly to changes in the 
requirements for dNTPs (Uhlin and Eklund, 1994). Regulation involves binding of 
effectors to two separate allosteric sites: specificity site (S-site) and activity site (A-
site). Recently, a third site, hexamerization site (H-site), has also been proposed to 
bind ATP to regulate RNR enzyme activity (Cooperman and Kashlan, 2003; Kashlan 
and Cooperman, 2003).  
The S-site binds to different allosteric effectors to influences substrate choice.  
When dATP binds to the S-site, the RNR enzyme binds and reduces CDP to dCDP 
and UDP to dUDP; when dTTP binds to the S-site, the enzyme binds and reduces 
GDP to dGDP; when dGTP binds to the S-site, the enzyme binds and reduces ADP to 
dADP. The S-site does not discriminate between ATP and dATP, so ATP also 
promotes reduction of CDP and UDP. Furthermore, dTTP is an inhibitor of pyrimidine 
reduction. In addition, dGTP is a negative feedback inhibitor of GDP reduction and 
also inhibits reduction of pyrimidines (Jordan and Reichard, 1998; Kolberg et al., 
2004; Nordlund and Reichard, 2006). 
The A-site modulates enzyme activity by monitoring the ATP/dATP ratio. 
Binding of ATP activates RNR and binding of dATP turns the enzyme off.  dATP acts 
as an overall negative regulator through inhibition of all four ribonucleotide 
reductions. Therefore, dATP has both stimulatory (S-site binding) and inhibitory (A-
site binding) effect. Because dATP has higher affinity to the S-site, the inhibitory 
effect is only significant at very high concentration of dATP. This feedback regulation 
ensures that a balanced dNTP pool is supplied for DNA synthesis.  
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Recent studies also suggest the R1 subunit contains a third regulation site (the 
hexamerization site, H-site). ATP binding to the H-site promotes the formation of an 
Rrm16-Rrm26 hexamer. This hexamer has been suggested to be the major active form 
of RNR in mammalian cells(Cooperman and Kashlan, 2003; Kashlan and Cooperman, 
2003). However, the presence of H-site and the Rrm16-Rrm26 hexamer is still highly 
controversial (Kolberg et al., 2004).  
 
1.2.3.2    Cell cycle regulation of RNR 
RNR is tightly regulated during the cell cycle through transcriptional 
expression, mRNA stability, and protein degradation. RNR enzyme activity increases 
greatly during S phase. R1 and R2 are regulated differentially, with R2 being rate 
limiting for enzyme activity (Bjorklund et al., 1990; Eriksson et al., 1984; Mann et al., 
1988).  
 
1.2.3.2.1 Transcriptional regulation of RNR during the cell cycle 
During an unperturbed cell cycle, the transcription of Rrm1 and Rrm2 is 
undetectable in G0/G1 phase and reaches maximal levels in S phase (Bjorklund et al., 
1990; Eriksson et al., 1984; Mann et al., 1988). However, the level of the Rrm1 
subunit is nearly constant throughout the cell cycle in proliferating cells, owing to its 
long half-life of more than 20 hours, and it is in excess relative to the Rrm2 subunit. 
Therefore, the cell cycle dependent RNR activity is controlled by synthesis and 
degradation of the Rrm2 subunit, which has a half-life of 3 hours. Rrm1 and Rrm2 
both contain promoter active regions (Nordlund and Reichard, 2006), which are 
controlled by S phase specific transcriptional machinery. Transcription of p53R2 is 
constant throughout the cell cycle, but is induced in response to DNA damage 
(Nakano et al., 2000; Tanaka et al., 2000). 
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The S phase specific transcription of the TATA-less mouse Rrm1 gene is 
controlled by proteins that bind to four different promoter elements, β (nucleotide -189 
to -167), α (-97 to -76), Inr (-4 to +16), and γ (+34 to +61) (Johansson et al., 1998). 
YY1, a ubiquitous transcription factor, binds to the β and α elements, which control 
the promoter strength.  The cell cycle-specific expression of Rrm1 is controlled by 
protein complexes containing TFII-I that bind to the Inr element and the downstream γ 
element (Johansson et al., 1998).  
Although the transcription of Rrm2 is tightly correlated to the cell cycle, less is 
known about the Rrm2 promoters responsible for this cell cycle regulated transcription 
(Chabes et al., 2004). Rrm2 promoters show no obvious sequence homologies with the 
Rrm1 promoters that could explain the common S phase specific expression pattern. 
Mouse Rrm2 promoter contains an atypical TATA –box with the sequence TTTAAA, 
which is not required for S –phase specific activity (Kotova et al., 2003). E2F4 binds 
to a repressive element of Rrm2 promoter to repress the Rrm2 transcription during 
G1/G0 phase. Binding of nuclear factor Y (NF-Y) to the Rrm2 promoter impedes the 
binding of E2F4 to this repressive site, and thus facilitates the release of E2F4 during 
S phase. In addition, an upstream activating region is also important for S phase 
specific transcription of Rrm2 gene. However, proteins binding to this activating 
region have not been identified (Chabes et al., 2004). 
 
1.2.3.2.2 mRNA stability 
In addition to transcriptional activation of gene expression, post-transcriptional 
mechanisms that alter mRNA message stability also play an important role in 
controlling message abundance and gene expression in mammalian cells.  
The Rrm1 gene contains a cis-element at the 3’-UTR of the mRNA that 
interacts with the R1BP protein complex. The Rrm2 gene also contains a cis-element 
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that interacts with the R2BP complex at the 3’-UTR of Rrm2 mRNA (Amara et al., 
1996; Angel et al., 1987; Burton et al., 2003; Chen et al., 1994). When cells are treated 
with potent tumor promoter, 12-O-tetradecanoylphorbol-13-acetate (TPA), the binding 
of R1BP and R2BP to their respective cis-elements is down-regulated, which 
correlates with an increase in Rrm1 and Rrm2 mRNA stability. The Rrm2 gene 
contains additional binding site at the 3’-UTR that binds to p75 in response to TGF-β 
stimulation and confers Rrm2 mRNA stability. The tumor promoter TPA and a DAG 
(1,2, diacylglycerol) analogue can activate PKC and cause elevation of Rrm1 and 
Rrm2 mRNA levels and prolong their half-life (Amara et al., 1996; Burton et al., 
2003; Chen et al., 1994). Thus, these two signaling pathways, PKC and TGF-β 
signaling pathways, regulate RNR message stability. Redox-sensitive mechanisms 
also play a role in R2BP/Rrm2 mRNA binding activity (Amara et al., 1996). Higher 
oxidation potential has also been found to be associated with progression with 
progression toward mitosis, therefore the control of many cell cycle proteins such  as 
RNR depend on redox-sensitive reactions (Goswami et al., 2000). Increasing oxidation 
during the cell cycle decreases the binding of R2BP, resulting in an increase in Rrm2 
mRNA stability, enabling the cell to increase its dNTP production for DNA synthesis 
(Burton et al., 2003). 
 
1.2.3.2.3 Post-translational regulation of RNR by the cell cycle 
In addition to transcriptional regulation and mRNA stability, the Rrm2 subunit 
is also regulated by enzyme degradation during mitosis in a cell cycle dependent 
manner. Rrm2 has a short half-life of 3 hours. RNR enzyme activity is therefore 
determined in part by the Rrm2 protein levels. Rrm2 protein accumulation is periodic; 
the polypeptide is absent during G0/G1-phase, peaks in S–phase, and then falls in 
mitosis due to proteolytic degradation (Chabes and Thelander, 2000; Chabes et al., 
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2003b; Eriksson et al., 1984).  
The mouse Rrm2 subunit contains an N-terminally located conserved KEN 
box (KENXXXN), a sequence recognized and ubiquitinated by the Cdh-anaphase-
promoting complex (Cdh1-APC). Cdh1-APC is an ubiquitin ligase that targets protein 
degradation during the mitosis and G1 phase. The overall periodicity of Rrm2 protein 
levels depends on this KEN box sequence. Mutating the KEN signal stabilizes the 
Rrm2 protein during mitosis and G1 phase (Chabes et al., 2003b). Additionally, Ser 20 
at the N-terminal tail of mouse Rrm2 protein is phosphorylated by p34cdc2 and CDK2 
protein kinases, which is also important for cell cycle regulation of the enzyme but the 
function of this phosphorylation has not been determined (Chan et al., 1993). 
However, the N-terminal sequence is not needed for enzyme activity since truncation 
of N-terminal residues in mouse Rrm2 does not significantly affect the enzyme 
activity (Mann et al., 1991). 
 
1.2.3.3    Subcellular localization regulation of RNR  
Translocation of RNR subunits from the cytosol to nucleus has been proposed 
to provide additional regulation of RNR. In mammals, it is well established that Rrm1 
and Rrm2 are cytoplasmic (Engstrom and Rozell, 1988; Engstrom et al., 1984), but the 
location of p53R2 and the translocation of Rrm1, Rrm2 and p53R2 after DNA damage 
are still controversial. Nakano and Tanaka both reported that p53R2 localizes to the 
nucleus in genotoxin treated cells, which may facilitate the localization of nucleotides 
at sites of DNA damage (Nakano et al., 2000; Tanaka et al., 2000). A study in a 
human tumor cell line showed that both Rrm2 and p53R2 undergo translocation from 
the cytosol to the nucleus coincident with activation of DNA synthesis (Liu et al., 
2005). In addition, translocation of Rrm1, Rrm2, p53R2 from the cytoplasm to the 
nucleus in response to UV irradiation is consistent with the increase in RNR activity 
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(Xue et al., 2003). However, a recent study found that all three RNR proteins reside in 
the cytosol independent of DNA damage, suggesting that dNTPs produced by RNR in 
the cytosol and diffuse into the nucleus or are transported into the mitochondria to 
support DNA replication and repair (Pontarin et al., 2008). Nuclear staining of p53R2 
was probably caused by non-specific staining of polyclonal antibodies, since cytosolic 
localization of p53R2 was detected by using specific monoclonal antibodies or affinity 
chromatography purified polyclonal antibodies in Pontarin’s report.  
In yeast, during the normal cell cycle, RNR1 and RNR3 are localized 
predominantly in the cytoplasm, whereas RNR2 and RNR4 have a primarily nuclear 
localization. In response to DNA damage, the small subunit complex RNR2/RNR4 
translocates from the nucleus to the cytoplasm, forming the active tetrameric RNR 
complex with the large subunit (Yao et al., 2003). Control of the nuclear localization 
of RNR2/RNR4 complex involves an anchor mechanism and Wtm1 is a key 
component of that anchor in budding yeast (Lee and Elledge, 2006; Zhang et al., 
2006). In addition, Damage regulated Import Faciliator 1 (Dif1) has been found to 
directly binds to the RNR2-RNR4 complex through a Hug domain to drive nuclear 
import of RNR2-RNR4 complex and Dif1 is both cell-cycle and DNA-damage 
regulated (Lee et al., 2008; Wu and Huang, 2008).  Thereby, the combination of both 
nuclear anchor limiting nuclear export and a regulated importer to coordinate 
subcellular localization of RNR has been proposed in budding yeast. In fission yeast, 
in addition to specifically binds and inhibit R1 (Cdc22p), inhibitory protein Spd1p can 
anchor the small subunit R2 in the nucleus (Hakansson et al., 2006a). 
 
1.2.3.4    Regulation of RNR by small inhibitory proteins 
 In some organisms, RNR activity can also be regulated by the binding of small 
inhibitory proteins, such as Sml1 in S. cerevisiae (Zhao et al., 1998) and Spd1 in S. 
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pombe (Hakansson et al., 2006a; Liu et al., 2003). Sml1 is a 104-residue peptide that 
binds the large subunit of RNR through its C-terminus and inhibit RNR enzyme 
activity by interfering with the regeneration of the catalytic site on the large subunit. 
Spd1 binds specifically to the Cdc22p (the large subunit R1 in fission yeast) to inhibit 
RNR activity. In addition to transcriptional induction of RNR following DNA 
damage, the Mec1 and Rad53 pathway also regulates RNR activity through 
phosphorylation and degradation of Sml1 inhibitory protein. Sml1 protein levels 
decrease during S phase and become undetectable after DNA damage, resulting in de-
repression of RNR activity. Failure to remove Sml1 in mec1 and rad53 mutants results 
in decreased dNTP levels, incomplete DNA replication, defective mitochondrial DNA 
propagation, and cell death (Zhao et al., 2001). Mutant strains lacking Sml1 grow 
normally, exhibit increased resistance to DNA-damage agents, and have higher dNTP 
levels compared to wild-type strains (Zhao et al., 1998). 
In mammalian cells, a Sml1-like mechanism for controlling the activity of 
RNR has not been identified.  However, p53 has been found to directly interact with 
p53R2 and Rrm2 but not Rrm1. After exposure to UV, p53R2 and Rrm2 have been 
suggested to dissociate from p53 and bind to Rrm1, forming Rrm1-Rrm2 and Rrm1-
p53R2 complexes to provide dNTPs for DNA repair (Xue et al., 2003).  
 
1.2.4 RNR and DNA damage response 
RNR plays an important role in DNA damage response and genome 
maintenance. In response to DNA damage and DNA replication blocks, all organisms 
arrest cell cycle progression at specific points and induce the expression of genes 
facilitating DNA repair. The largest category of DNA damage-inducible genes are 
those involved in DNA replication, including DNA polymerases and RNR genes. 
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Induction of these genes in response to stress of DNA damage is thought to produce a 
metabolic state that facilitates DNA replication and repair processes.  
Consistent with a need for nucleotides during DNA repair, DNA damage 
induces transcription of the RNR genes in both yeast and mammalian cells, in a 
manner dependent on DNA damage checkpoint signaling pathways (reviewed in 
(Elledge et al., 1993) see also (Filatov et al., 1996; Guittet et al., 2001; Hakansson et 
al., 2006b; Nakano et al., 2000; Tanaka et al., 2000; Zhao et al., 2001). In yeast, RNR 
is the best-studied transcriptional target of the Mec1 and Rad53 checkpoint pathway. 
Dun1, a downstream kinase of the Mec1/Rad53 pathway, activates transcription of 
RNR genes in response to DNA damage (Chen et al., 2007b; Zhao and Rothstein, 
2002; Zhou and Elledge, 1993). Dun1 was originally identified in yeast as a mutant 
showing a defect in the up-regulation of RNR in response to DNA damage (Zhou and 
Elledge, 1993). In addition to transcriptional activation of RNR, Dun1 is also 
responsible for phosphorylation and degradation of the RNR inhibitory protein Sml1 
in response to DNA damage (Zhao and Rothstein, 2002). Dun1-dependent regulation 
of the localization of different RNR subunits in response to DNA damage serves as an 
additional mechanism for RNR activation in DNA damage response (Lee and Elledge, 
2006; Zhang et al., 2006). Collectively, in yeast, DNA damage results in a substantial 
increase in dNTP levels. This increase in dNTP pools dramatically improves survival 
following DNA damage (Chabes et al., 2003a). 
Like in yeast, activation of checkpoint pathways promotes the delay of cell 
cycle progression in mammalian cells, allowing required repair to take place before 
commencement of DNA replication and mitosis. DNA double-stranded breaks (DSBs) 
and stalled DNA replication forks prompt the activation of Atm (ataxia telangiectasia-
mutated) and Atr (AT and Rad3-related) signaling pathways. Activated Atm and Atr, 
on one hand, recruit Mdc1, p53BP1 and Brca1 to sites of DNA damage to facilitate 
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repair and simultaneously propagate the checkpoint signals to Chk2/p53 and Chk1 to 
block G2/M transition and S phase progress. p53R2 is targeted by the p53-dependent 
checkpoint pathway through transcriptional activation in response to DNA damage 
(Nakano et al., 2000; Tanaka et al., 2000). Concomitantly, the level of Rrm2 is 
repressed in a p53 dependent manner (Lin et al., 2004; Tanaka et al., 2000).  
It has been suggested that mammalian Rrm1 and Rrm2 are DNA damage-
inducible. The Rrm1 promoter is induced up to 3-fold and the Rrm2 promoter is 
induced up to 10-fold by UV light at a dose-dependent manner (Filatov et al., 1996). 
Rrm2 protein is stabilized in response to DNA damage (Chabes and Thelander, 2000). 
Several studies found that Rrm2 can substitute for the function of p53R2 in providing 
dNTPs for DNA repair in cells lacking functional p53 (Lin et al., 2004) and excess 
Rrm2 protein functions coordinately with the S phase checkpoint to contend with 
DNA damage and alleviate replication stress (Lin et al., 2007).  
The finding of the DNA damage-inducible p53R2 gene resolved the mystery of 
how non-proliferating cells with no detectable Rrm2 proteins would obtain dNTPs for 
DNA repair after DNA damage. In mammalian cells, ATM activates p53, which then 
induces the expression of p53R2 by directly activating its transcription through 
binding of a sequence in the first intron of the p53R2 gene(Nakano et al., 2000; 
Tanaka et al., 2000). P53R2 protein forms an active Rrm1-p53R2 complex with Rrm1 
to provide dNTPs for DNA repair (Guittet et al., 2001; Hakansson et al., 2006b). Cells 
that can not make p53R2 protein are more sensitive to DNA-damaging agents (Tanaka 
et al., 2000; Yamaguchi et al., 2001). Recent studies found that ATM directly 
phosphorylates p53R2 at Ser72 in response to genotoxic stress and this modification is 
essential for maintaining p53R2 protein stability (Chang et al., 2008). ATM dependent 
p53R2 phosphorylation at Ser72 regulates cell viability and p53R2 protein stability by 
inhibiting p53R2 hyper-ubiquitination and degradation by MDM2 in response to DNA 
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damage (Chang et al., 2008). Together, transcriptional induction of p53R2 by p53 
and/or phosphorylation of p53R2 by ATM are responsible for providing dNTPs by 
Rrm1-p53R2 complex for DNA repair following DNA damage. 
It is still unclear whether dNTP levels also increase after DNA damage in 
mammalian cells. Mammalian cells have a more strict dATP feedback inhibition of 
RNR activity, so increased levels of RNR enzyme in mammalian cells might not result 
in a general increase in the dNTP pools (Akerblom et al., 1981). The p53-dependent 
induction of the p53R2 protein is important in the cellular response to DNA damage 
(Nakano et al., 2000; Tanaka et al., 2000), and by analogy with the yeast system, it has 
been assumed that mammalian cells also increase their RNR activity and dNTP pools 
after DNA damage (Lin et al., 2004). However, there are conflicting reports on the 
effect of DNA damage on dNTP pools in mammalian cells (Kunz and Kohalmi, 1991). 
A recent study found no major increase in the dNTP pools in logarithmically growing 
or resting mammalian cells after DNA damage, which is in strong contrast to the 
pronounced increase in dNTP pools observed in yeast after DNA damage (Hakansson 
et al., 2006b). 
In summary, in response to DNA damage, cellular dNTP levels increase by 
several fold due to the elevation of RNR activity through transcriptional induction, 
inactivation of the RNR negative regulator sml1, and changes in subcellular 
translocation, as discussed above. Up-regulated RNR activity can rescue the lethality 
caused by mutations of essential cell cycle checkpoint genes Mec1/Rad53 in yeast 
(Desany et al., 1998; Zhao et al., 1998). Mammalian cells with increased RNR activity 
are also resistant to particular DNA damaging agents (Huang et al., 1997).  In the 
context of DNA damage response, the increase in dNTP levels may be necessary for 
repair synthesis, and translesion DNA polymerases need higher concentration of 
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dNTPs to bypass DNA lesions (Chabes et al., 2003a). Therefore, up-regulated RNR is 
beneficial to cell survival following DNA damage.  
 
1.3    Deregulation of RNR and genome instability 
Although up-regulated RNR promotes cell survival following DNA damage, 
abundant evidence shows that deregulation of RNR is mutagenic, causing increased 
mutation rates in both yeast (Chabes et al., 2003a) and mammalian cells (Caras and 
Martin, 1988). Deregulation of RNR might cause genomic instability through two 
major different mechanisms: imbalanced dNTP pools resulting from altered RNR 
enzyme activity and increased oxidative DNA damage resulting from increased radical 
production. 
1.3.1 Genomic instability induced by deregulated dNTP synthesis enzyme 
RNR plays a dominant role in tightly regulating dNTP pool sizes and 
composition. Hence the control of RNR activity is important not only in regulating the 
kinetics of DNA replication, but also in maintaining the integrity of the genome 
(Herrick and Sclavi, 2007). Deregulation of RNR is mutagenic in both yeast and 
mammalian cells, which is largely due to elevated dNTP levels or altered dNTP ratios 
generated by increased RNR activity (Caras and Martin, 1988; Chabes et al., 2003a; 
Weinberg et al., 1981; Zhou et al., 1998a). The observation of severe mitochondrial 
DNA (mtDNA) depletion in humans with p53R2 mutations demonstrates that p53R2 
has a crucial role in maintaining dNTP supply, especially for the synthesis of mtDNA, 
which constantly replicates. 
As with RNR deregulation, deregulation of other enzymes involved in dNTP 
biosynthesis also leads to enhanced mutagenesis and genomic instability. Cdh1-
APC/C not only controls RNR degradation in a cell cycle dependent manner, but also 
degrades thymidine kinase (TK1) and thymidylate kinase (TMPK), two enzymes 
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controlling dTTP synthesis, during mitosis. When these control mechanisms are shut 
off by mutating the KEN box in those two proteins, dTTP accumulates in a 
unbalanced fashion, causing an increase in spontaneous mutation rates and genomic 
instability (Ke et al., 2005). Thus, the tight regulation of enzymes controlling dNTP 
synthesis and the post-S phase shutoff of dNTP synthesis play a key role in 
maintaining optimal genomic stability (Mathews, 2006). 
The connection between RNR deregulation and enhanced mutagenesis is still 
not fully understood. Allosteric regulation of RNR by dATP inhibition keeps the S 
phase dNTP pools at a level that is optimal for replication, which does not increase 
even when the limiting Rrm2 protein is overproduced. In hydroxyurea-resistant Rrm2-
overproducing mouse cells having 3-15 times higher RNR activity than the parent 
cells, all dNTP pools were close to normal, except for a 3-4 times higher dATP pools 
(Akerblom et al., 1981). Furthermore, hydroxyurea-resistant, Rrm2 over-producing 
mouse mammary tumor TA 3 cells, containing about 40 fold higher Rrm2 protein than 
parent cells, had the same dNTP pools as the parent cells (Eriksson et al., 1984). In 
both of these cases, the cell cycle regulation of the Rrm2 protein was not disturbed 
(Chabes and Thelander, 2000). In contrast, in mouse cells containing Rrm1 protein 
with a D57N mutation in the allosteric activity site, which abolishes the dATP 
feedback inhibition, dNTP pools increased 3-9 fold and the spontaneous mutation rate 
was about 100 times higher than the parent cells (Weinberg et al., 1981). However, 
another study found Rrm1-D57N mutant produced mutator phenotype in mammalian 
cells without significant changes in dNTP pools (Caras and Martin, 1988). Therefore, 
whether the enhanced mutagenesis associated with RNR deregulation resulted from 
perturbations of dNTP pools has not been established. 
Despite the well-established association between RNR and maintenance of 
genome integrity, the mechanisms of genomic instability caused by RNR deregulation 
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have not been conclusively determined. In addition to possibly altered enzyme activity 
and changes in dNTP pools, other mechanisms may also contribute to genomic 
instability associated with RNR deregulation. 
 
1.3.2 RNR deregulation and oxidative DNA damage 
The small subunit of RNR produces a radical for catalysis and shows dynamic 
carboxylate, radical, and water shifts in different redox form (Kolberg et al., 2004). 
The structure and function of RNR is closely linked to its redox state.  Free radicals let 
loose in the cell can perpetrate all kinds of damage, including mutagenesis and 
molecular degradation (Stubbe, 1994). Similarly, cytochrome c oxidase, which has 
redox active tyrosine in the binuclear center, participates in reducing oxygen in 
respiration, suggesting that proteins containing tyrosyl radicals with a binuclear center 
may be reducing or oxidizing reagents (Xue et al., 2006). It has been reported that 
human RRM2 protein produces reactive oxygen species (ROS) in vitro (Xue et al., 
2006). Thus, free radical-induced oxidative DNA damage might also contribute to the 
mutagenic effect of RNR deregulation. ROS can cause DNA damage, which has long 
been thought to be involved in carcinogenesis by amplifying genomic instability. 
However, p53R2 is indicated to play a key role in defending against oxidative stress 
by scavenging ROS (Xue et al., 2006). 
 
1.4    RNR and cancer 
Large amounts of dNTPs are required for the replication of the genome in 
proliferating cells during the S phase of cell cycle, whereas in the other phase the 
requirement is low. The level of RNR in mammalian cells is therefore closely linked 
with cell cycle and growth control mechanism. Elevations in RNR activity have been 
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reported to be linked to neoplastic properties of cells (Wright et al., 1990), malignant 
transformation and cancer metastasis.  
 
1.4.1 RNR and transforming activity 
Preliminary evidence had suggested that Rrm1 may function as a tumor 
suppressor (Bepler et al., 2002; Fan et al., 1997; Gautam et al., 2003) and has 
malignancy-suppressing activity. Stable expression of Rrm1 in a Ras-transfected 
mouse fibroblast cell line resulted in reduced anchorage-independent growth and 
tumor formation in syngeneic mice (Fan et al., 1997). Rrm1 has been also found to 
function as a metastasis suppressor gene through induction of PTEN expression. 
Overexpression of Rrm1 in human and mouse lung cancer cell lines induced PTEN 
expression, reduced phosphorylation of focal adhersion kinase (FAK), suppressed 
migration, invasion, and metastasis formation (Gautam et al., 2003). 
Rrm2 has been suggested to play a direct role in determining malignant 
potential through cooperating with oncogenes. R2 is not only capable of acting in 
cooperation with a variety of oncogenes (H-ras, rac-1, v-fms, v-src, A-raf, v-fes, and 
c-myc) to promote anchorage-independent growth and tumor formation, but also 
enhances cancer invasive potential (Fan et al., 1998; Fan et al., 1996; Zhou et al., 
1998b).  
p53R2, on the other hand, has been proposed to have tumor suppressor activity 
based on its regulation by p53 and its role in the DNA damage response (Tanaka et al., 
2000). Given that many human tumors contain mutations in p53, discovery of p53R2 
thus created a link between one of the most important tumor suppressor and the 
synthesis of deoxyribonucleotides (Xue et al., 2003).  
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1.4.2 RNR and human cancer 
In humans, RRM1 is located on chromosome segment 11p15.5, a region with 
frequent loss of heterozygosity in non-small-cell lung cancer (NSCLC) (Bepler et al., 
2002; Pitterle et al., 1999). Low levels of expression of the gene are associated with 
poor survival among patients with NSCLC (Bepler et al., 2004). RRM1 protein 
expression in NSCLC cells is nuclear, highly correlated with ERCC1 expression, and 
significantly associated with prolonged cancer-free and overall survival in untreated 
early-stage NSCLC (Zheng et al., 2007). However, RRM1 overexpression has been 
linked to drug resistance in tumor chemotherapy, and is utilized as a marker for 
chemoresistance and poor survival in patients with advanced NSCLC (Ceppi et al., 
2006; Gazdar, 2007) . Thus, RRM1 in NSCLC has been proposed to have a dual role 
in both cancer susceptibility and drug resistance by repairing DNA lesions during the 
early stage of the cancer to promote survival and by repairing the drug-DNA adducts 
formed after chemotherapy to cause drug resistance and poor survival during the late 
stage of the cancer (Gazdar, 2007). 
RRM2 expression level was correlated with both advanced breast tumor grade 
and stage, suggesting that RRM2 may play a dual role in supporting both rapid cell 
proliferation and invasive growth (Ma et al., 2003). The genomic regions containing 
human RRM2 (2p25-2p24) are commonly amplified in human lung cancers (Pei et al., 
2001; Wong et al., 2003). Human RRM2 gene expression levels and gene 
amplification have also been correlated with chemotherapy drugs (for example, 
docetaxel/gemcitabine) resistance and clinic outcomes of lung adenocarcinomas 
(Souglakos et al., 2008; Zhou et al., 2001).  
p53R2 gene is localized to chromosome 8q23.1 and several tumors have been 
noted to have losses of  this chromosome region. A few reports have suggested 
potential implications of p53R2 in human squamous cell carcinomas and  NSCLC 
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(Uramoto et al., 2006; Yanamoto et al., 2003). In addition, a number of 
polymorphisms in the gene encoding p53R2 have been identified in esophageal 
squamous cell carcinoma and in colon carcinoma (Deng et al., 2005; Smeds et al., 
2001; Yamaguchi et al., 2001), but none of these mutations are associated with altered 
p53R2 activity (Chang et al., 2008).  
The level of RNR tyrosyl radical is dependent on the oxygenation of the cells, 
where the radical disappears when the cells are deprived of oxygen (Probst et al., 
1989). Human cancer cells with an increased level of R2 resume S phase progression 
faster upon re-oxygenation after exposure to moderate hypoxia than cells with a 
normal level of RNR (Graff et al., 2002). Cells are thus given less time for DNA 
repair, which would result in an increased probability of mutations.  This indicates 
how an increased level of RNR might raise the malignant potential of tumors (Fan et 
al., 1998; Fan et al., 1996).  
 
1.4.3 RNR as a target for cancer therapy 
Tumor cells are more sensitive to the cytotoxic effect of RNR inhibition than 
normal cells because of the increased need for dNTPs for proliferation and decreased 
adaptability and low responsiveness to regulatory signals. Thus the enzyme has long 
been considered an excellent target for cancer chemotherapy (Shao et al., 2006). 
Specific inhibitors of RNR such as hydroxyurea and substrate analogues such as 
Gemcitabine have long been used for treatment of cancer. Hydroxyurea is a radical 
scavenger and it inactivates RNR by directly reducing the tyrosyl radical of the R2 
subunit to a normal tyrosine residue via one-electron transfer from the drug (Shao et 
al., 2006). Hydroxyurea inhibits both RRM2 and p53R2 (Shao et al., 2004) and is 
commonly used for the treatment of chronic myelogenous leukemia and 
thrombocythemia. Overexpression of RRM2 increases resistance to hydroxyurea in 
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cancer cells and RRM2 gene amplification and alterations in transcriptional regulation 
are probably responsible for the mechanism of the drug resistance (Shao et al., 2006).   
 
1.5    Models of RNR deregulation 
Several models have been established to study the effect of RNR deregulation. 
In yeast, up-regulated RNR activity, through overproduction of Rnr1, inactivation of 
the inhibitory protein Sml1, or a mutation in allosteric activity site (rnr1-D57N), can 
rescue the lethality caused by mutations of the essential cell cycle checkpoint genes 
Mec1/Rad53. However, this increased survival is at the expense of increased 
mutagenesis due to the increase in dNTP levels.  In cultured mammalian cells, 
expression of Rrm1-D57N mutant protein results in a mutator phenotype, with a15-25 
fold increase in spontaneous mutation rates. However, no significant dNTP pool 
changes were observed in this study (Caras and Martin, 1988). In addition, Rrm1 and 
Rrm2 overexpressing 3T3 cells were generated and Rrm2 overexpressing cells found 
to have transforming activity in cooperation with variety of oncogenes. 
Overexpression of Rrm1 in 3T3 cells, on the other hand, was found to have tumor 
suppressing activity. 
In mouse models, p53R2 knockout mice die from severe renal failure by the 
age of 14 weeks and show attenuated dNTP pools and higher rates of spontaneous 
mutation in the kidneys, suggesting that p53R2 has an essential role in maintaining 
dNTP levels for repair of DNA in resting cells (Kimura et al., 2003). In addition to 
kidney failure, p53R2 knockout mice show growth retardation, muscle atrophy and 
had a markedly decreased mtDNA content at 12 weeks of age, suggesting that p53R2 
has a crucial role in dNTPs supply for the synthesis of mtDNA, which constantly 
replicates  (Bourdon et al., 2007). Recently, Rrm1 transgenic mice were generated and 
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showed significantly suppressed carcinogen-induced lung tumor formation and higher 
efficiency in chemical-induced damage repair (Gautam and Bepler, 2006).  
 
1.6    Summary 
RNR catalyzes the rate-limiting step of dNTP biosynthesis and plays an 
essential role in DNA replication and DNA repair. Due to its critical role in genome 
maintenance, RNR activity is tightly regulated through S phase specific transcription 
of Rrm1 and Rrm2 genes, binding of allosteric effectors to Rrm1 protein, anaphase 
promoting complex-cdh1-mediated degradation of the Rrm2 protein during late 
mitosis. Deregulation of RNR has been found to cause genomic instability in both 
yeast and mammalian cells.  
Although RNR enzyme activity has long been associated with cancer cell 
proliferation and RNR inhibition is an effective strategy for cancer therapy, the 
connection between RNR and cancer development is still unclear. It is critical to 
establish whether RNR deregulation will initiate and promote cancer progression. We 
hypothesize that deregulation of RNR, by overexpressing each RNR subunit in mice, 
would cause genomic instability and cancer development. The aim of this dissertation 
is to elucidate the physiological effect of RNR deregulation using the transgenic 
mouse models and to further dissect the molecular mechanisms of RNR-induced 
tumorigenesis. 
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CHAPTER 2 
 
Broad Overexpression of Ribonucleotide Reductase Genes in Mice 
Specifically Induces Lung Neoplasms 
 
2.1 Abstract 
Ribonucleotide reductase catalyzes the rate-limiting step in nucleotide 
biosynthesis and plays a central role in genome maintenance. Although a number of 
regulatory mechanisms govern RNR activity, the physiological impact of RNR 
deregulation had not previously been examined in an animal model. We demonstrate 
here that overexpression of the small RNR subunit potently and selectively induces 
lung neoplasms in transgenic mice and is mutagenic in cultured cells. Combining RNR 
deregulation with defects in DNA mismatch repair, the cellular mutation correction 
system, synergistically increased RNR-induced mutagenesis and carcinogenesis. 
Moreover, the proto-oncogene K-ras was identified as a frequent mutational target in 
RNR-induced lung neoplasms. Together, these results demonstrate that RNR 
deregulation promotes lung carcinogenesis through a mutagenic mechanism and 
establish a new oncogenic activity for a key regulator of nucleotide metabolism. 
Importantly, RNR-induced lung neoplasms histopathologically resemble human 
papillary adenocarcinomas and arise stochastically via a mutagenic mechanism, 
making RNR transgenic mice a valuable model for lung cancer. 
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2.2 Introduction 
An adequate and balanced supply of deoxyribonucleotide triphosphates 
(dNTPs) is essential for accurate DNA replication and repair. The rate limiting step in 
de novo dNTP biosynthesis is catalyzed by the enzyme ribonucleotide reductase 
(RNR). RNR reduces ribonucleoside diphosphate (NDP) to deoxyribonucleoside 
diphosphate (dNDP), phosphorylation of which yields dNTP. RNR is composed of 
two non-identical homodimeric subunits (Nordlund and Reichard, 2006). The large R1 
subunit harbors the catalytic site and is encoded by the Rrm1 gene in mammals. The 
small R2 subunit contains an oxygen-bridged dinuclear iron center that generates a 
tyrosyl free radical that is transferred to the R1 subunit for enzyme activity. 
Mammalian genomes contain two independent genes, Rrm2 and Rrm2b (p53R2), that 
encode closely related R2 proteins. A complex of Rrm2 and Rrm1 accounts for most 
RNR activity during S phase. p53R2 was originally identified as a target gene for the 
p53 tumor suppressor protein and is transcriptionally induced following DNA damage 
(Nakano et al., 2000; Tanaka et al., 2000). In addition to its role in stress responses, 
p53R2 is expressed at low levels throughout the cell cycle and complexes with Rrm1 
to produce dNTPs for mitochondrial DNA replication (Pontarin et al., 2007).  
Because intracellular nucleotide concentrations have a major impact on DNA 
replication fidelity (Mathews, 2006), RNR enzyme activity is tightly controlled by 
several regulatory mechanisms. During an unperturbed cell cycle, the transcription of 
Rrm1 and Rrm2 is undetectable in G0/G1 phase and reaches maximal levels in S phase 
cells (Bjorklund et al., 1990; Eriksson et al., 1984; Mann et al., 1988). However, 
owing to its long half-life, Rrm1 protein levels are nearly constant throughout the cell 
cycle and in excess relative to the R2 subunit. RNR enzyme activity is therefore 
determined in part by R2 protein levels. Rrm2 protein is absent during G0/G1-phase, 
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peaks in S–phase, and then falls in mitosis following ubiquitination by the anaphase 
promoting complex (Chabes and Thelander, 2000; Chabes et al., 2003b; Eriksson et 
al., 1984). Consistent with a need for nucleotides during DNA repair, DNA damage 
and replication stress induce RNR expression in both yeast and mammalian cells, in a 
manner dependent on DNA damage checkpoint pathways (Elledge et al., 1993; 
Hakansson et al., 2006b). While mammalian Rrm1 and Rrm2 proteins are cytoplasmic 
(Engstrom and Rozell, 1988), p53R2 localizes to the nucleus in genotoxin-treated cells 
(Nakano et al., 2000; Tanaka et al., 2000), which may facilitate the localized 
production of nucleotides at DNA damage sites. 
RNR enzyme activity also is controlled by two allosteric sites in the R1 
subunit. A specificity site regulates the relative cellular concentration of each of the 
four dNTPs by influencing substrate choice, while an activity site regulates the total 
dNTP pool size by monitoring the ATP/dATP ratio. Analysis of the mutant Rrm1-
D57N, which is insensitive to feedback inhibition by dATP due to a mutation in the 
activity site, indicates that loss of RNR allosteric control results in a mutator 
phenotype in both yeast and mammalian cells (Caras and Martin, 1988; Chabes et al., 
2003a; Reichard et al., 2000).  
Although RNR is a major determinant of genomic integrity, the consequences 
of RNR deregulation in animals are unknown. We generated transgenic mice that 
overexpress Rrm1, Rrm2, or p53R2 and found that overexpression of either small 
RNR subunit induced spontaneous lung neoplasms and was mutagenic in cultured 
cells. Defects in DNA mismatch repair (MMR) synergistically increased RNR-
induced mutagenesis and carcinogenesis, and activating mutations in the proto-
oncogene K-ras were identified in lung neoplasms from Rrm2 and p53R2 transgenic 
mice. These results identify mutagenic and carcinogenic effects of RNR deregulation 
in vivo. 
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2.3 Material and methods 
2.3.1 Plasmids.   
Expression plasmids encoding mouse Rrm1, Rrm2, or p53R2 were constructed 
in the pCaggs expression vector (Niwa et al., 1991) as follows. The mouse Rrm1 
cDNA sequence was cloned as an XhoI fragment from clone D65 (Thelander and 
Berg, 1986) into XhoI-digested pCaggs plasmid, producing pCaggs-Rrm1. The Rrm2 
open reading frame was PCR amplified with primers 5’-
AGAGCTCGAGCCATGCTCTCCGTCCGCAC-3’ and 5’-
AGAGCTCGAGTTAGAAGTCAGCATCCAAGGT-3’ using clone C10 (Thelander 
and Berg, 1986) as a template. The resulting PCR product was digested with XhoI and 
cloned into XhoI-digested pCaggs plasmid, producing pCaggs-Rrm2. The p53R2 open 
reading frame was PCR amplified from EST clone AA623971 with primers 5’-
GCGGAATTCATGGGCGACCCGGAAAGG-3’ and 5’-
GCGGAATTCTTAGAAATCTGCATCCAAGGT-3’. The resulting PCR product was 
digested with EcoRI and cloned into EcoRI-digested pCaggs plasmid, producing 
pCaggs-p53R2. All PCR products were fully sequenced and confirmed to be free of 
mutations.  
 
2.3.2 Transgenic mice. 
Transgenic mice were generated by microinjection of linear plasmid DNA into 
the pronucleus of zygotes derived from FVB/N mice as previously described (Muller 
et al., 1988). SalI-linearized pCaggs-Rrm1, SalI/BamHI-digested pCaggs-Rrm2, and 
SalI/PstI-digested pCaggs-p53R2 were used. Transgenic founder mice were initially 
identified by Southern blot analysis using probes specific for Rrm1, Rrm2, or p53R2. 
Transgenic mice were maintained as hemizygotes on a pure FVB/N background by 
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breeding with wild-type FVB/N mice. Genotyping was performed by PCR with 
primers: 5’-ATCAGAAGGTGGTGGCTGGTGTGG-3’ and 5’-
GCTATGACTGGGAGTAGTCAGGAG-3’ for Rrm1 and p53R2; 5’-
AGAGCTCGAGCCATGCTCTCCGTCCGCAC-3’ and 5’-
GCTAAATCGCTCCACCAAGTTCTC-3’ for Rrm2. For analysis of tumor 
development, cohorts of mice were aged until moribund for 15 to 21 months. As part 
of another study, some RNR transgenic mice were bred with mice heterozygous for a 
targeted deletion of the Hus1 cell cycle checkpoint gene. Hus1+/- mice show no 
apparent phenotypes (Weiss et al., 2000) and as expected no differences in tumor 
incidence or any other phenotypes were noted between Hus1+/- (n=74) and Hus1+/+ 
(n=183) mice in the cohort. Therefore, the Hus1 genotype is not distinguished in the 
final data set consisting of 257 mice (Table 1). Msh6-null mice (Edelmann et al., 
1997) were obtained from the Mouse Models of Human Cancers Consortium and bred 
with Rrm2Tg or p53R2Tg mice to generate Msh6+/-RNRTg mice. Msh6+/-RNRTg mice 
were crossed with Msh6+/- or Msh6-/- mice to produce littermates of the following 
genotypes: Msh6-/-RNRTg, Msh6-/-, Msh6+/-RNRTg, Msh6+/-, Msh6+/+RNRTg , and 
Msh6+/+. Mice were aged until moribund for 6 or 17 months depending on the 
experiment and analyzed as noted above. All mice were maintained identically, 
following guidelines approved by the Cornell University Institutional Laboratory 
Animal Use and Care Committee. 
 
2.3.3 Pathological assessment.  
Mice terminated according to schedule, as well as those with visible neoplasms 
or showing signs of clinical disease, including hunched posture, labored breathing, 
poor grooming, and wasting, were euthanized by asphyxiation using carbon dioxide 
and necropsied. Inflated lungs and other affected tissues were fixed with 10% neutral-
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buffered formalin, embedded in paraffin and 4-5 µm thick sections were stained with 
hematoxylin and eosin. If needed for molecular biological and biochemical studies, a 
part of freshly dissected tissues was snap-frozen in liquid nitrogen and kept at -80ºC. 
Pathological assessment was performed according to guidelines endorsed by the 
Mouse Models of Human Cancers Consortium (Nikitin et al., 2004).  
 
2.3.4 Immunohistochemistry. 
Immunohistochemistry was performed using the Vectastain ABC kit (Vector 
Laboratories) on 5 µm paraffin sections. Briefly, endogenous peroxidase was 
quenched using 3% H2O2 in distilled water. Sections were blocked for 2 h at RT in 
TBS containing 4% normal goat serum and 10% non-fat milk and then incubated for 2 
h at 37°C in TBS containing 0.04% Triton-X100 and Anti-pro-SP-C (Chemicon 
International; 1:500 dilution) or anti-CC10 (Santa Cruz Biotechnology; 1:250 
dilution). Sections then were washed with TBS, incubated for 30 min at RT with 
biotinylated anti-IgG antibody (Vector Laboratories), and incubated with ABC 
complex diluted in blocking solution for 30 min at RT. Staining was done with a 
peroxidase substrate kit (Vector Laboratories) according to manufacturer 
recommendations. Counterstaining of sections was performed with methyl green 
(Fisher Scientific). 
 
2.3.5 Generation of RNR overexpressing 3T3 cell pools. 
 All cells were cultured in culture medium (Dulbeco’s Modification of Eagles 
Medium supplemented with 10% bovine calf serum, 1.0 mM L-glutamine, 0.1 mM 
MEM non-essential amino acids, 100 µg/ml of streptomycin sulfate, and 100 U/ml of 
penicillin). Mouse 3T3 fibroblasts were transfected with linearized empty pCaggs 
vector, pCaggs-Rrm1, pCaggs-Rrm2, or pCaggs-p53R2 along with PGK-puro using 
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FuGENE 6 transfection reagent (Roche Diagnostics Co., Mannheim, Germany) 
following the procedure recommended by the manufacturer. At 48 hours, the medium 
was replaced with selection medium containing 1 mg/ml puromycin, which was 
changed every 2 days. After 2 weeks, puromycin-resistant cells were pooled and 
expanded for further analysis under selection conditions.  
 
2.3.6 Northern blot analysis. 
Total RNA was isolated from cultured cells or mouse tissues using RNA 
STAT-60 (Tel-Test Inc.). Approximately 2.5 µg of each RNA was resolved on a 1% 
agarose/formaldehyde gel and then hybridized with probes specific to mouse Rrm1, 
Rrm2, p53R2, or Gapdh. 
 
2.3.7 Western blot analysis.  
Tissue samples or cultured cells were prepared in RIPA buffer (50mM Tris-
HCl [pH 8.0], 1% [vol/vol] Nonidet P-40, 0.5% sodium deoxycholate, 0.1% [wt/vol] 
sodium dodecyl sulfate, 150mM sodium chloride, 50mM sodium fluoride) and 1x 
protease inhibitor cocktail (Roche). Immunoblotting was performed on PVDF 
membranes using standard methods, with signal detection by enhanced 
chemiluminescence (Pierce). The antibodies used were mouse anti-R1 (AD203, Bio 
Med Tek), goat anti-R2 (sc-115, Santa Cruz Biotechnology,), rabbit anti-p53R2 (2383, 
ProSci-inc,) and β-actin (A5441, Sigma). 
 
2.3.8 Hprt mutation rate assay. 
Cells were maintained in HAT medium (culture medium supplemented with 
0.2mM sodium hypoxanthine, 0.4µM aminopterin, 0.02µM thymidine [GIBCO]) for 
two weeks. Cells then were maintained in HT medium (culture medium supplemented 
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with 0.1mM sodium hypoxanthine, 0.016µM thymidine [GIBCO]) for one week. 
Subsequently, cells were seeded at a density of 5x105 cells per 10cm plate (10 plates 
total) in culture medium containing 5µg/ml 6-thioguanine (Sigma). After 3 weeks, 6-
thioguanine resistant colonies were counted, isolated, and individually expanded.  
RNA was extracted, and cDNA was synthesized with primer 5’-
GCAGCAACTGACATTTCTAAA-3’ using the SuperscriptTM First Strand Synthesis 
System (Invitrogen). The Hprt open reading frame was PCR amplified using primers: 
5’-TTTCCGGAGCGGTAGCAG-3’ and 5’-TTACTAGGCAGATGGCCACA-3’. 
Hprt mutations were identified by direct sequencing of PCR products using primers: 
5’-CTTCCTCCTCAGACCGCTTT-3’ and 5’-TGGCAACATCAACAGGACTC-3’. 
Plating efficiency was determined by plating 200 cells in medium without 6-
thioguanine in triplicate for 2 weeks and counting stained colonies. 
 
2.3.9 Big Blue mutation rate assay. 
Big Blue C57Bl/6 mice (Jakubczak et al., 1996), hemizygous for the lambda 
shuttle vector, were obtained from Stratagene (La Jolla, CA) and were bred with 
Rrm1, Rrm2, or p53R2 hemizygous transgenic mice. Genomic DNA was isolated from 
3-month old lung tissues by phenol-chloroform extraction using the RecoverEase 
DNA isolation kit protocol (Stratagene, LA Jolla, CA). The bacteriophage λ transgene 
was recovered from genomic DNA by incubation with in vitro λ packaging extract 
(Transpack; Stratagene) according to the manufacturer’s instruction. Phage containing 
cII mutations were identified by mixing 100µl of packaged phage with 200µl of an 
overnight culture of E. coli G1250 cells. This solution was mixed with TB-1 top agar, 
poured onto TB1 plates, and incubated at 24°C for 48 h. To determine the total 
number of phage screened, 10 µl of a 1:100 dilution of packaged phage was mixed 
with 200µl of G1250, plated on TB1 plates in triplicate, and incubated at 37°C for 24 
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h. The mutant plaques were confirmed by re-plating on TB1 plates at 24°C. For cII 
sequencing, well-isolated, clear plaques (phages with cII mutants) were picked and 
PCR amplified (forward primer: 5’-CCGCTCTTACACATTCCAGC-3’, reverse 
primer: 5’-CCTCTGCCGAAGTTGAGTAT-3’). Mutations in λ cII gene were 
identified by direct sequencing of the PCR products using primer 5’-
CCACACCTATGGTGTATG-3’. Mutation frequencies were compared using a 
Maximum Likelihood Ratio test and two-way ANOVA. 
 
2.3.10 Determination of mutation rates in Saccharomyces cerevisiae. 
All yeast strains were derived from either W4069-4C (WT) or W4069-8C 
(rnr1-D57N1) (Chabes et al., 2003a).  These strains are derived from the W303 strain. 
Mutations in the mismatch repair genes were introduced into these strain backgrounds. 
The msh2D::hisG, msh6D::hisG and msh3D::hisG alleles have complete or nearly 
complete disruptions of their respective genes and were introduced into these strains 
by single-step gene transplacement (Alani et al., 1987). The spontaneous forward 
mutation rate to canavanine resistance (Canr) was measured in W4069-4C (WT), 
W4069-8C (rnr1-D57N1), EAY1997-2000 (msh3∆), EAY2001-2003 (rnr1-D57N 
msh3∆), EAY2004-2006 (msh2∆), EAY2007-2009 (rnr1-D57N msh2∆), EAY2010-
2013 (msh6∆), EAY2014-2019 (rnr1-D57N msh6∆) as described previously (Reenan 
and Kolodner, 1992). Briefly, independent cultures from at least 3 independent 
isolates of each genotype were plated for single colonies at 30°C on YPD plates. 
Appropriate dilutions of cells from single colonies (~2 mm) were plated on: 1) 
synthetic complete (SC) medium lacking arginine to determine the number of viable 
cells and 2) SC-Arg plus L-canavanine (60 mg/ml) to determine the number of Canr 
cells per culture. The rate of mutation per generation was calculated from the median 
mutation frequency using the method of Lea and Coulson (Lea and Coulson, 1949). 
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The mutation rate and 95% confidence interval were determined from at least 22 
independent measurements for each strain. To determine mutation spectra, the CAN1 
gene was PCR amplified with primers AO1863: 5'-TCAGGGAATCCCTTTTTGCA-
3’ and AO257: 5'-GTGAGAATGCGAAATGGCGTG-3’ and sequenced with primers 
AO256: 5'-AGTTCTTCAGACTTCTTAACTC-3’, AO1864: 5'-
CCAGTGGGCGCTCTTATA-3’, AO1865: 5'-TTACCGGCCCAGTTGGAT-3’, 
AO1866: 5'-CAACCATTATTTCTGCCG-3’, AO1977: 5'-
CACCCAAGGACTGCGTGACAG-3’.   
 
2.3.11     Sequencing of K-ras exons 1 and 2. 
5 µm sections of lung tumor samples were microdissected with a Leica Laser 
Microdissection instrument and incubated in proteinase K buffer (150 µg/ml 
proteinase K in Taq DNA polymerase PCR buffer [MI188J, Promega]) at 50°C for 4h. 
The sample was heated at 100°C for 10 min to inactivate the proteinase K and then 
centrifuged at 4000 rpm for 2 min. The supernatant was used for PCR amplification of 
K-ras exons 1 and 2 with the following primer sets: (5’-
CCATGTATTTTTATTAAGTGTTGA-3’ and 5’-
CTCCTCGAGCAAGCGCACGCAGACTGTAGAGCA-3’ for exon 1) and (5’-
CTCGAATTCATCCTAATGGGTACTAATGGTGT-3’ and 5’-
CTCCTCGAGAGCAAAGAATCAATAAATGTAAGC-3’ for exon 2). Mutations in 
K-ras exons 1 and 2 were identified by direct sequencing of the PCR products using 
the following primers: (5’-CTATAATGGTGAATATCTTC-3’ for exon 1) and (5’-
CTCTATCGTAGGGTCGTACT-3’ for exon 2). 
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2.4 Results 
2.4.1 Generation of RNR transgenic mice and analysis of transgene expression. 
Deregulation of RNR is mutagenic in yeast and cultured mammalian cells 
(Caras and Martin, 1988; Chabes et al., 2003a). To test the consequences of RNR 
deregulation in an animal model, we set out to generate transgenic mice featuring 
broad, high level expression of the individual mouse RNR genes Rrm1, Rrm2, and 
p53R2, using pCaggs expression constructs that place the RNR genes under the 
control of chicken β-actin promoter and cytomegalovirus enhancer regulatory 
sequences. Six Rrm1, two Rrm2, and four p53R2 transgene-positive founders were 
generated and subsequently maintained on a pure FVB/N strain background.  RNR 
transgenic mice appeared grossly normal and were fertile. When bred with wild-type 
FVB mice, p53R2 hemizygotes produced fewer than the expected number of transgene 
positive offspring (205 p53R2 transgene positive and 349 transgene negative mice 
were identified among 554 mice genotyped at weaning). 
Endogenous and transgenic Rrm1, Rrm2 and p53R2 mRNA expression was 
tested in a variety of organs by Northern blot analysis. The endogenous Rrm1 and 
Rrm2 genes were coordinately expressed, with highest expression in proliferative 
tissues such as testis and thymus (Fig. 2.1A, left panels). Expression of the 
endogenous p53R2 gene was undetectable in all tested wild-type FVB tissues. 
Importantly, Rrm2Tg and p53R2Tg mice showed high-level transgene expression in all 
tissues, with overexpression being highest in muscle (Fig. 2.1A, right panels). Rrm1 
overexpression was only observed in muscle and testis of Rrm1Tg mice. For technical 
reasons, the Rrm1 transgene included additional non-coding cDNA sequences and was 
microinjected as a linearized construct without removal of plasmid backbone 
sequences, which may contribute to the relatively poor transgene expression.  
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Figure 2.1. Widespread overexpression of ribonucleotide reductase genes in transgenic 
mice. (A) Northern blot analysis of RNR expression in wild-type and RNR transgenic 
mice. Total RNA was extracted from the indicated tissues from wild-type FVB mice 
(left panels), or RNR transgenic mice (right panels) and subjected to Northern blot 
hybridization with the indicated probes specific for Rrm1, Rrm2 or p53R2. Positions 
of endogenous and transgene-derived RNR transcripts are indicated. (B) Western blot 
analysis of RNR protein expression in the indicated tissues from wild type (WT) and 
RNR transgenic (Tg) mice, as well as lung neoplasms from the corresponding 
transgenic strains (Tumor 1, 2). Total protein from the indicated tissues was subjected 
to immunoblotting with antibodies specific to Rrm1, Rrm2 or p53R2. Duplicate 
membranes were immunoblotted for β-actin as a loading control.
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Consistent with results from the Northern blot analyses, immunoblotting 
revealed that the Rrm2 and p53R2 proteins were highly overexpressed in all tested 
tissues from Rrm2Tg and p53R2Tg mice (Fig. 2.1B). Although Northern blotting failed 
to identify p53R2 expression in wild-type tissues (Fig. 2.1A), low levels of p53R2 
protein were apparent in most wild-type FVB tissues. Rrm1 protein overexpression 
was limited to muscle and to a lesser extent lung in Rrm1Tg mice as compared to wild-
type littermates. Together, these results establish the restricted overexpression of the 
large RNR subunit Rrm1 and the widespread, high level overexpression of the small 
RNR subunits Rrm2 and p53R2 in transgenic mice.  
 
2.4.2 Overexpression of the small RNR subunit promotes lung carcinogenesis. 
In order to identify spontaneous neoplasms and other abnormalities in RNR 
transgenic mice, we established a cohort consisting of 52 Rrm1Tg, 75 Rrm2Tg, and 81 
p53R2Tg mice, as well as 49 transgene-negative control mice, and aged them until they 
exhibited clinical illness. Notably, a significantly increased frequency of lung 
neoplasms was observed in Rrm2Tg and p53R2Tg mice (Table 2.1). 72% of Rrm2Tg and 
74% of p53R2Tg animals developed spontaneous lung neoplasms. By contrast, 31% of 
transgene-negative controls developed lung neoplasms, a frequency consistent with 
the reported incidence for aged wild-type FVB mice (Mahler et al., 1996). The lung 
neoplasm incidence in Rrm1Tg mice was 31%, identical to that of the control animals 
and significantly less than that of Rrm2Tg or p53R2Tg mice (Chi-square analysis, 
p<0.05). Lung neoplasms were observed in multiple independent Rrm2Tg and p53R2Tg 
lines, indicating that transgene integration site effects did not account for the 
neoplastic phenotype. Signs of clinical illness arose following a latency of 16-18 
months for all genotypes. No differences in lung neoplasm incidence between sexes  
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Table 2.1 Lung neoplasm characteristics in RNR overexpressing mice 
 
 
 
 
 
 
 
 
 
NOTE: Mice were aged until moribund for up to 21 months, euthanized by 
asphyxiation using carbon dioxide, and subjected to pathological examination as 
described in Materials and Methods.  
 
†WT FVB refers to transgene-negative control mice. 
 
§Includes mice that had both epithelial hyperplasia of alveoli and lung neoplasms. 
 
*Statistically significant difference (p<0.05) relative to WT FVB mice. Incidences 
were compared by Chi-square analysis. Neoplasm sizes were compared by t-test 
analysis. 
Mouse 
 genotype 
# of 
animal
s 
% of mice  
with lung 
neoplasms 
% of mice 
 with 
 hyperplasia§ 
Average  
lung neoplasm 
size (mm)±SD 
% of mice  
with multiple 
lung neoplasms 
% of  mice  
with lung 
adenocarcinoma 
WT FVB† 49 31% 12% 4.04 ± 3.98 8% 6% 
Rrm1Tg 52 31% 15% 3.96 ± 3.59 8% 10% 
Rrm2Tg 75 72%* 44%* 6.68 ± 4.22 53%* 40%* 
p53R2Tg 81 74%* 20% 4.26 ± 3.44 47%* 21% 
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was noted for any of the transgenic lines. The frequency of epithelial hyperplasia of 
alveoli also was increased in p53R2Tg and especially Rrm2Tg mice. Other neoplasms, 
including papilloma, histiocytic sarcoma, mammary carcinoma, and lymphoblastic 
lymphoma, were observed in 13% of Rrm1Tg, 12% of Rrm2Tg, and 12% of p53R2Tg 
mice, but only 2% of transgene-negative mice. 
The lung neoplasms in Rrm2Tg and p53R2Tg mice displayed several features 
consistent with a substantial lung cancer predisposition. A significantly greater lung 
neoplasm multiplicity was observed for Rrm2Tg and p53R2Tg mice, and the lung 
neoplasms in Rrm2Tg mice were also considerably larger than those from control 
animals (Table 2.1). The lung neoplasms from Rrm2Tg and p53R2Tg mice ranged from 
adenoma to advanced adenocarcinoma (Fig. 2.2A I-VI), and resembled human 
glandular pulmonary neoplasms, particularly adenocarcinomas. RNR-induced lung 
adenocarcinomas were primarily of the papillary subtype and exhibited pleural 
invasion, heterogeneous growth pattern, nuclear atypia, high mitotic index, and blood 
vessel invasion (Fig. 2.2A III-VI).  A greater frequency of adenocarcinoma was 
observed in Rrm2Tg and p53R2Tg mice as compared to Rrm1Tg or transgene-negative 
mice (Table 2.1), with Rrm2 overexpression in particular eliciting pathologically 
advanced neoplasms. Together, these data indicate that overexpression of either small 
RNR subunit in mice promotes lung neoplasm formation, with Rrm2 being more 
potent than p53R2 with respect to tumor size, multiplicity, and malignancy.  
To investigate the possible cell type of origin for RNR-induced lung 
neoplasms, we performed immunohistochemistry using antibodies against Clara cell 
antigen (CC10) and surfactant apoprotein-C (SP-C), markers that distinguish Clara 
and alveolar type II cells, respectively. Eight of eight lung neoplasms from Rrm2Tg and 
p53R2Tg mice were positive for SP-C (Fig. 2.2A VII), while none was positive for 
CC10 (Fig. 2.2A VIII). Adjacent bronchioles, on the other hand, were positive for  
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Figure 2.2 Histopathological and molecular analysis of lung neoplasms from RNR 
transgenic mice. (A) (I) Lungs from a Rrm2Tg mouse with multiple independent 
neoplasms affecting several lobes. (II-VI) H&E-stained sections of lung neoplasms. 
(II) Solid adenoma from a p53R2Tg mouse. (III-VI) Papillary adenocarcinomas from 
Rrm2Tg or p53R2Tg mice showing pleural invasion (arrow) (III), regional variation in 
growth pattern (IV), multiple mitotic figures (arrows) (V), and blood vessel invasion 
(arrow) (VI). (VII, VIII) Immunohistochemical staining of RNR-induced lung 
neoplasms for Pro-SP-C (VII) or CC10 (VIII) by the ABC method, with methyl green 
counterstain. Inserts show higher magnification views of the boxed regions. 
Calibration bar: II, IV: 50 µm; III: 241 µm; V: 10 µm; VI: 25 µm; VII, VIII: 100 µm. 
(B) Northern blot analysis of lung neoplasms from RNR transgenic mice. Total RNA 
was prepared from lung neoplasms (Tumor 1, Tumor 2, Tumor 3) or normal lung 
tissue (Lung) from RNR transgenic mice, as well as from wild-type FVB lung tissue 
(WT FVB). Northern blotting was performed with the indicated radiolabeled probes. 
(C) Western blot analysis of Rrm1 expression in lung neoplasms (Tumor 1, Tumor 2) 
or normal lung tissues (lung) from RNR transgenic mice as well as normal lung from 
wild-type FVB lung tissue (WT FVB) . Total protein was subjected to immunoblotting 
with antibody specific to Rrm1 or α-tubulin as a loading control.
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Figure 2.2 (continued)
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CC10 and negative for SP-C as expected. These results suggest that RNR-induced 
lung neoplasms arose from alveolar type II cells or their progenitors. 
To confirm a causative role for RNR overexpression in lung carcinogenesis, 
we analyzed the expression of Rrm1, Rrm2, and p53R2 in lung neoplasms by Northern 
(Fig. 2.2B) and Western (Fig. 2.1B) blotting. Lung neoplasms from Rrm2Tg and 
p53R2Tg animals showed prominent RNR overexpression, consistent with a causative 
role for RNR in the genesis of these lung lesions. By contrast, lung neoplasms from 
Rrm1Tg mice did not display high level transgene expression, providing further 
evidence that carcinogenesis in Rrm2Tg and p53R2Tg mice is highly specific. Overall, 
these data identify a novel oncogenic activity for the small RNR subunit. 
Previous studies suggest that Rrm1 has tumor suppressor activity (Bepler et al., 
2002; Fan et al., 1997; Gautam et al., 2003). Lung neoplasms in Rrm2Tg and p53R2Tg 
mice showed slightly lower Rrm1 mRNA expression levels compared to normal lung 
tissues from these transgenic mice in Northern blot analysis (Fig 2.2B). In order to test 
whether enhanced lung tumorigenesis in Rrm2Tg or p53R2Tg mice is associated the 
down-regulation of Rrm1, we analyzed Rrm1 protein levels in lung neoplasms from 
RNR transgenic mice by western blotting. As shown in Fig. 2.2C, there was no 
difference in the expression of Rrm1 protein in these lung lesions induced by small 
RNR subunit overexpression, suggesting that lung tumorigenesis in Rrm2Tg and 
p53R2Tg mice is not due to down-regulated Rrm1 protein levels. 
Rrm1Tg mice did not show increased lung carcinogenesis, which might be due 
to the fact that the R2 subunit is the limiting component of the enzyme. To test 
whether overexpression of the large subunit Rrm1 would enhance lung tumorigenesis 
induced by Rrm2 or p53R2 overexpression, we crossed Rrm1Tg mice to Rrm2Tg or 
p53R2Tg mice to generate RNR bi-transgenic mice. We established a cohort consisting 
of 14 Rrm1TgRrm2Tg, 9 Rrm1Tgp53R2Tg, 13 Rrm1Tg , 4 Rrm2Tg, and 6 p53R2Tg mice, as  
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well as 9 transgene negative controls, and aged them until they exhibited clinical 
illness up to about 17 months. As shown in table 2.2, 93% (13/14) of Rrm1TgRrm2Tg 
bi-transgenic mice developed spontaneous lung neoplasms, which was not 
significantly different than the lung tumor incidence in Rrm2Tg mice (100%, 4/4); 
similarly, 56% (5/9 ) of Rrm1Tgp53R2Tg bi-transgenic mice exhibited lung neoplasms, 
which was not significantly different with lung tumor incidence of p53R2Tg mice (67% 
; 4/6). Consistent with the data from the cohort of mice with the individual RNR 
transgenes, 22% (2/9) transgene negative control mice and 8% (1/13) Rrm1Tg 
transgenic mice developed spontaneous lung neoplasms. In addition, compared to 
Rrm2Tg mice, Rrm1TgRrm2Tg bi-transgenic mice showed no differences in the 
frequency of multiple lung neoplasms and adenocarcinomas. Similarly, when 
compared to p53R2Tg mice, Rrm1Tgp53R2Tg bi-transgenic mice showed no difference 
in lung tumor multiplicity.  In addition, we did not observed an increased incidence of 
other tumor in these Rrm1TgRrm2Tg and Rrm1Tgp53R2Tg bi-transgenic mice as 
compared to either Rrm2Tg or p53R2Tg mice.  These data suggest that the 
overexpression of the large RNR subunit does not enhance lung tumorigenesis induced 
by the small RNR subunit.  
 
2.4.3 Increased mutation frequency following RNR overexpression in cultured 
3T3 cells. 
We hypothesized that RNR overexpression induced lung neoplasms through a 
mutagenic mechanism because defects in RNR allosteric control result in increased 
mutation frequencies in yeast and mammalian cells (Caras and Martin, 1988; Chabes 
et al., 2003a). To determine if RNR overexpression was similarly mutagenic, we 
generated Rrm1, Rrm2, or p53R2 overexpressing 3T3 cell pools using the same 
expression constructs as used to generate the transgenic mice. Overexpression of  
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Table 2.2 Lung neoplasm characteristics in RNR bi-transgenic mice 
 
 
 
 
 
 
 
 
 
 
 
 
 
NOTE: Mice were aged until moribund for about 500 days, euthanized by 
asphyxiation using carbon dioxide, and subjected to pathological examination as 
described in Materials and Methods.  
 
†WT FVB refers to transgene-negative control mice. 
 
*Statistically significant difference (p<0.05) relative to WT FVB mice. Incidences 
were compared by Chi-square analysis. Neoplasm sizes were compared by t-test 
analysis. 
 
§ Other neoplasms including lymphoma, ovary tumor, urinary bladder tumor.  
 
Mouse 
 genotype 
# of 
animals 
Age 
(days) 
% of mice  
with lung 
neoplasms 
Average  
lung neoplasm 
size (mm)±SD 
% of mice  
with 
multiple 
lung 
neoplasms 
% of  mice  
with lung 
adenocarcinoma 
% of  mice  
with other 
neoplasms§ 
WT FVB† 9 508 22% 8.0 ± 8.5 0% 11% 11% 
Rrm1Tg 13 466 8% 6.00 ± 0 0% 8% 0% 
Rrm2Tg 4 489 100%* 5.3 ± 3.3 100%* 50%* 25% 
p53R2Tg 6 516 67%* 1.6 ± 1.1 50%* 0% 0% 
Rrm1Tg Rrm2Tg 14 427 93%* 6.4 ± 2.9 100%* 57%* 21% 
Rrm1Tg p53RTg 9 461 56%* 4.7 ± 2.9 40%* 30% 33% 
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individual RNR genes in these cell pools was confirmed by Northern and Western 
blotting (Fig. 2.3A and B). We then measured mutation frequency using the Hprt 
mutation detection assay, which identifies cells harboring Hprt mutations by virtue of 
their resistance to 6-thioguanine (6-TG) (Fenwick, 1985). In a representative 
experiment (Fig. 2.3C), a significantly increased mutation frequency was observed in 
a Rrm2 overexpressing cell pool (9.0 X 10-6) as compared to Rrm1 overexpressing or 
empty plasmid vector cell pools (less than 0.7 X 10-6 and 0.8 X 10-6, respectively). 
Three independent Rrm2 overexpressing cell pools showed a consistently increased 
mutation frequency that was 9.9- to 16.0-fold greater than that observed for vector 
control cells. A p53R2 overexpressing cell pool showed a more modestly but 
nevertheless significantly increased mutation frequency of 3.0 X 10-6 (Fig. 2.3C). 
However, mutation frequency in p53R2 overexpressing cells varied, with three p53R2 
overexpressing cell pools showing an elevated mutation frequency that was 4.2- to 
11.2-fold greater than that for vector control cells while two other p53R2 
overexpressing cell pools displayed no increase in mutation frequency. Whether this 
variability is due to differences in expression levels between individual cell pools, or 
to the fact that the mutation frequencies measured were near the lower end of 
sensitivity for this assay, has not been determined.  However, three independent Rrm1 
overexpressing cell pools and another five empty plasmid vector cell pools showed no 
detectable increase in mutation frequency.  
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Figure 2.3 Increased mutation frequency in RNR overexpressing NIH/3T3 cell pools. 
(A) Northern blot analysis of RNR expression in stable 3T3 cell pools transfected with 
either pCaggs empty vector or pCaggs RNR genes. Total RNA was extracted from the 
indicated cell lines and subjected to Northern blot hybridization with probes specific 
for Rrm1, Rrm2, p53R2, or Gapdh. (B) Western blot analysis of RNR protein 
expression in RNR overexpressing 3T3 cells. Total protein was extracted from the 
indicated cell lines and subjected to immunoblotting with antibodies specific to Rrm1, 
Rrm2, or p53R2. Duplicate membranes were immunoblotted for b-actin as a loading 
control. Samples in (A) and (B) were run on single blots, which were then cropped to 
remove extraneous lanes. (C) Mutation frequency at the Hprt locus in Rrm1, Rrm2 and 
p53R2 overexpressing 3T3 cells. Mutation frequency was determined by Hprt assay.
54 
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To determine the nature of the mutations conferring 6-TG resistance, we 
sequenced the Hprt gene from individual colonies (Wijnhoven et al., 2000).  
Interestingly, four of seven Hprt mutations from the Rrm2 overexpressing cell pool 
shown in Fig. 2.3C were G→T substitutions (Table 2.3), which are relatively rare 
among reported spontaneous Hprt mutations (Zhang et al., 1992). Similar results were 
obtained in a separate experiment with an independent Rrm2 overexpressing cell pool 
(Table 2.3). One of six mutations from the p53R2 overexpressing cell pool shown in 
Fig. 2.3C also was a G→T mutation, but no G→T mutations were observed among six 
6-TG resistant clones from a second independent experiment (Table 2.3). Collectively, 
the results indicate that overexpression of the small RNR subunit causes a mutator 
phenotype.  
 
2.4.4 Combined defects in RNR regulation and MMR result in synergistic 
increases in mutagenesis and carcinogenesis.  
To further evaluate a role for mutagenesis in RNR-induced lung 
carcinogenesis, we investigated whether combining RNR deregulation with a defect in 
MMR, the repair system that suppresses mutation accumulation, would cause a 
synergistic increase in mutagenesis and carcinogenesis. In eukaryotes, a complex of 
Msh2-Msh6 is responsible for recognizing base-base mispairs and single base 
insertion/deletions, while a Msh2-Msh3 complex detects larger insertion/deletion 
loops (Modrich, 2006). We first tested this hypothesis in S. cerevisiae by measuring 
the mutation rate by canavanine resistance assay in strains with deregulated RNR 
activity and mutations in MMR genes. To deregulate budding yeast RNR, we utilized 
the rnr1-D57N mutant in which a single amino acid change in the R1 activity site 
makes the enzyme insensitive to feedback inhibition by dATP 
56 
   Table 2.3 Mutational spectrum at the Hprt locus in RNR overexpressing cell pools 
Cell pool Clone ID Mutation† Amino acid change 
1 355 G>T G>Stop codon 
2 106 del G Stop codon 
3§ 568 G>T G>Stop codon 
4 602 A>G D>G 
Rrm2-A 
5 403 ins AG stop codon 
1 403-404 GA>TT‡ D>F 
2 584 A>C Y>S 
3 613 G>T V>F 
4§ 403-404 GA>TT‡ D>F 
5§ 389 T>G V>G 
6§ 584 A>C Y>S 
Rrm2-B 
7 403-404 GA>TT‡ D>F 
1 643 A>G K>E 
2 581 A>T D>V 
3§ 542 T>C F>S 
4 581 A>T D>V 
5 530 A>G D>G 
p53R2-A 
6 542 T>C F>S 
1§ 586 A>G N>D 
2 586 A>G N>D 
3 635 G>A G>E 
4 409 A>T I>F 
5§ 609-626 del Stop codon 
p53R2-B 
6 544 G>T E>Stop codon 
NOTE: 6-thioguanine resistant colonies were isolated and expanded from the indicated cell pools. 
RNA was extracted for cDNA synthesis and the Hprt gene coding region was amplified by PCR. 
Mutations in the Hprt cDNA were identified by directly sequencing PCR products. These data 
represent results from two independent experiments done with independent RNR overexpressing cell 
pools (A and B). The mutation frequencies shown in Fig. 1C are for cell pools Rrm2-B and p53R2-
B.  
 
†The numerical value indicates the position of the mutated nucleotide followed by the specific 
sequence change. 
 
§Additional, independent colonies on the same plate had the same mutation as these clones and were 
excluded as clonal events. 
 
‡These clones also expressed low levels of a smaller transcript that had a deletion of nucleotides 403-
470. 
57 
(Caras and Martin, 1988). Consistent with published reports (Chabes et al., 2003a), 
rnr1-D57N yeast exhibited a 3.4-fold increase in mutation rate relative to the wild-
type strain, which had a mutation rate of 1.5 X 10-7 (Fig. 2.4). MMR defective strains 
also displayed elevated mutation rates (msh2Δ: 28.4-fold; msh3Δ: 2.9-fold; msh6Δ: 
9.8-fold), similar to previous reports (Lau et al., 2002). Notably, rnr1-D57N msh2Δ 
and rnr1-D57N msh6Δ double mutants displayed approximately multiplicative 
increases in mutation rate relative to the single mutants (61.4-fold and 23.8-fold, 
respectively). Multiplicative increases in mutagenesis are seen for mutations that 
affect factors acting in series in a common pathway (Morrison et al., 1993), suggesting 
that the Msh2-Msh6 complex corrects DNA mismatches induced by RNR 
deregulation. By contrast, combining rnr1-D57N with msh3Δ resulted in only an 
additive increase in mutation rate (rnr1-D57N msh3Δ: 3.9-fold). The spectrum of 
mutations arising in WT, rnr1-D57N, msh2Δ, and msh6Δ strains was consistent with 
previous publications (Chabes et al., 2003a; Lau et al., 2002; Marsischky et al., 1996) 
and included primarily base substitutions, as well as frameshift mutations for msh2Δ 
(Table 2.4). The frequency of frameshift mutations involving single nucleotide 
insertions or deletions was substantially increased in rnr1-D57N msh2Δ and rnr1-
D57N msh6Δ strains relative to the single mutants.  
The synergistic effects of RNR deregulation and MMR deficiency on mutation 
rates in yeast prompted us to further test genetic interactions between RNR and MMR 
in mice, by crossing RNR transgenic mice with Msh6-null mice (Edelmann et al., 
1997). If RNR overexpression induces lung carcinogenesis through a mutagenic 
mechanism, Msh6 deficiency would be predicted to accelerate lung carcinogenesis in 
RNR transgenic mice. A cohort of Msh6-/-, Msh6+/-, or Msh6+/+ mice that also carried 
either the Rrm2 or p53R2 transgene was established and examined for survival and 
cancer susceptibility. Interestingly, the median lifespan for Msh6-/-p53R2Tg mice (136  
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Figure 2.4 Genetic interactions between RNR and mismatch repair in yeast. 
Canavanine mutation rate assay for RNR1(WT) and rnr1-D57N strains on MMR-
deficient backgrounds (msh3Δ, msh2Δ, msh6Δ, or WT) of S. cerevisiae. The forward 
mutation rate (per generation) to canavanine resistance was measured for the indicated 
single and double mutant combinations.  Error bars show the 95% confidence interval. 
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Table 2.4. Mutational spectrum at the CAN1 locus in wild-type and rnr1-D57N yeast 
strains that vary in mismatch repair status 
NOTE: The CAN1 gene was PCR amplified from Canr colonies and directly sequence. 
WT (4C)   
rnr1-
D57N 
(8C) 
  msh2∆ (4C/98)   
msh6∆ 
(4C/108)   
rnr1-D57N 
msh2∆ 
(8C/98) 
  
rnr1-D57N 
msh6∆ 
(8C/108) Type of mutation 
# %  # %  # %  # %  # %  # % 
Base 
substitut
ion                  
GC pair 6 55%  10 63%  4 31%  15 68%  3 18%  14 37% 
AT pair 3 27%  3 19%  2 15%  3 14%  0 0%  8 21% 
Frame 
shift                  
Deletion 1 9%  1 6%  6 46%  1 5%  4 24%  12 32% 
Insertion 0 0%  2 12%  1 8%  3 14%  10 59%  4 11% 
Large 
deletion 1 9%  0 0%  0 0%  0 0%  0 0%  0 0% 
                  
Total 11 100%   16  100%   13 100%   22 100%   17 100%   38  100% 
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days) was significantly reduced compared to that of transgene-negative Msh6-/- mice 
(258 days; p<0.05; logrank test) (Fig. 2.5). The reduced survival of Msh6-/-p53R2Tg 
mice was associated with early onset lymphomagenesis (Table 2.5). Because these 
Msh6-/-p53R2Tg mice died at a young age, we could not evaluate whether Msh6 
deficiency cooperated with p53R2 overexpression in inducing lung neoplasms. 
The survival rate for Msh6-/-Rrm2Tg and  transgene negative Msh6-/- mice was not 
significantly different (p=.975; logrank test), suggesting that Rrm2 overexpression, 
unlike p53R2 overexpression, did not enhance lymphomagenesis (Fig. 2.5). However, 
that 90% of Msh6-/-Rrm2Tg mice had developed lung neoplasms despite their shortened 
lifespan of approximately 10 months was suggestive of a synergistic genetic 
interaction (Table 2.5). To directly test whether lung carcinogenesis was accelerated in 
Msh6-/-Rrm2Tg mice, we sacrificed a cohort of Msh6-/-Rrm2Tg mice and littermate 
controls at 6 months of age. 3 of 18 Msh6+/+Rrm2Tg mice and 3 of 17 Msh6+/-Rrm2Tg 
mice had developed lung neoplasms by 6 months, while no lung neoplasms were 
observed in transgene-negative Msh6+/+ or Msh6+/- littermates (Table 2.6). Lung 
neoplasms were also observed in 2 of 13 Msh6-/- mice. Msh6 deficiency strongly 
accelerated Rrm2-induced lung carcinogenesis, as 13 of 13 Msh6-/-Rrm2Tg mice 
developed lung neoplasms by 6 months of age, with 9 of these mice carrying multiple 
lung neoplasms.  
To determine whether combining RNR overexpression with MMR deficiency 
would increase mutation frequency in vivo, we analyzed the mutation frequency at the 
λ phage cII locus in lung tissue from 3 month old RNRTg mice, with or without Msh6 
deficiency, using the Big Blue transgene system (Jakubczak et al., 1996). There was 
no difference in mutation frequency in RNR transgenic mice as compared to wild-type 
mice (Fig. 2.6A and Table 2.7), possibly because the Big Blue system is relatively 
insensitive due to a high background mutation frequency. However, the mutation 
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Figure 2.5 Genetic interactions between RNR and mismatch repair in mice. Survival 
curves for Msh6-/-RNRTg (Rrm2Tg or p53R2Tg) mice. Mice were aged until moribund for 
up to 17 months. Survival curves were generated using SPSS software. The following 
number of animals was analyzed for each genotype: Msh+/+ (11), Msh6+/- (23), Msh6+/-
Rrm2Tg (22), Msh6+/-p53R2Tg (11), Msh6-/- (34), Msh6-/-Rrm2Tg (20), Msh6-/- p53R2Tg 
(17). 
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Table 2.5 Combining RNR overexpression with mismatch repair 
deficiency results in a synergistic increase in tumorigenesis 
NOTE: Mice were aged for up to 17 months, euthanized by asphyxiation using 
carbon dioxide, and subjected to pathological examination as described in 
Materials and Methods.  
 
†Other neoplasms include gastrointestinal, liver, skin, and uterine neoplasms. 
Mouse genotype 
Number 
of  
animals 
Median 
 age of death 
Number of mice 
with lung neoplasms 
(%) 
Number of mice 
with lymphoma 
(%) 
Number of 
mice 
with other 
neoplasms† 
(%) 
Msh6-/- p53R2Tg 17 136 4 (24%) 16 (94%) 2 (12%) 
Msh6-/- Rrm2Tg 20 316 18 (90%) 15 (75%) 7 (35%) 
Msh6-/- 34 258 12 (35%) 29 (85%) 8 (24%) 
Msh6+/- p53R2Tg 11 519 4 (36%) 0 (0%) 1 (9%) 
Msh6+/- Rrm2Tg 22 510 21 (96%) 1 (5%) 2 (9%) 
Msh6+/- 23 518 6 (26%) 3 (13%) 0 (0%) 
Msh6+/+ p53R2Tg 4 519 2 (50%) 0 (0%) 1 (25%) 
Msh6+/+ Rrm2Tg 2 503 2 (100%) 0 (0%) 0 (0%) 
Msh6+/+ 11 518 3 (27%) 0 (0%) 2 (18%) 
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Mouse genotype 
# of 
animals 
% of mice 
with lung 
neoplasms 
% of mice 
with 
 multiple 
lung 
neoplasms 
# of lung 
neoplasms per 
mouse† ±SD 
Average 
lung neoplasm 
size (mm)±SD 
% of  mice 
 with 
lymphoma 
Msh6-/-Rrm2Tg 13 100%* 69%* 2.9 ± 1.99 1.30 ± 0.54 31% 
Msh6-/- 13 15% 0% 1.0 ± 0 1.25 ± 1.06 8% 
Msh6+/-Rrm2Tg 17 18% 0% 1.0 ± 0 0.73 ± 0.68 12% 
Msh6+/- 10 0% 0% N/A N/A 0% 
Msh6+/+Rrm2Tg 18 17% 6% 1.33 ± 0.58 1.23 ± 0.25 0% 
Msh6+/+ 14 0% 0% N/A N/A 0% 
 
 
 
 
 
 
 
 
 
Table 2.6. Combining RNR overexpression with mismatch repair deficiency 
results in a synergistic increase in lung carcinogenesis 
NOTE: Mice were aged for 6 months, euthanized by asphyxiation using carbon 
dioxide, and subjected to pathological examination as described in Materials and 
Methods. Only mice that lived to 6 months were included. Four Msh6-/-Rrm2Tg mice 
died before 6 months due to lymphoma, one of which also had a lung neoplasm. Four 
Msh6-/- mice died before 6 months due to lymphoma.  
 
†Values refer to the average number of lung neoplasms per mouse among tumor-
bearing animals only. 
 
*Statistically significant difference (p<0.01) relative to Msh6-/-, Msh6+/-Rrm2Tg, or 
Msh6+/+Rrm2Tg mice as determined by Fisher’s Exact test. 
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Figure 2.6 Synergistic effect on mutagenesis when combining RNR and mismatch 
repair defects in mice. Mutation frequency at the λ cII locus in lung (A) or spleen (B) 
tissues from RNR overexpressing and control mice. Genomic DNA was isolated 
from 3-month old mice of the indicated genotypes and packaged into infectious 
phage. Mutation frequency was determined based on the ratio of the number of 
mutant phage obtained to the total number of phage analyzed.
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Table 2.7. Analysis of mutation frequencies at the cII locus of a bacteriophage l   
transgene in lung tissue from Msh6-/- RNRTg and control mice 
Stain Animal ID 
Age 
(days) Sex 
Total 
number 
of 
plaques 
Number 
of 
mutants 
Mutation 
frequency 
Mutation 
frequency 
(Avg ± 
SD) 
6378 90 F 341550 16 4.7 
6394 98 M 366948 23 6.2 
6469 102 M 579466 25 4.3 
6793 92 F 264000 20 7.6 
6830 91 M 269500 11 4.1 
6864 93 F 363000 17 4.7 
WT 
3682 95 M 286000 18 6.3 
5.5±1.3 
6380 90 F 260000 10 3.8 
6468 102 M 332133 23 6.9 
6470 102 M 341000 9 2.6 
6465 133 F 284715 21 7.4 
6466 133 F 264000 16 6.1 
Rrm1Tg 
6832 91 M 260333 15 5.8 
5.4±1.9 
6395 98 M 247250 14 5.7 
6397 98 M 173600 14 8.1 
6895 93 M 418000 29 6.9 
6896 93 M 286000 11 3.8 
6900 93 F 82830 4 4.8 
3681 95 M 363000 11 3.0 
 
Rrm2Tg 
3463 96 M 341667 10 2.9 
5.0±2.0 
6359 57 F 463833 23 4.9 
6790 93 F 402800 35 8.7 
6862 92 F 198000 13 6.6 
 
p53R2Tg 
3378 91 F 423333 24 5.7 
6.5±1.6 
3676 95 F 357500 78 21.8 
3750 96 F 455000 133 29.2 Msh6-/- 
3752 96 M 220000 92 41.8 
31.3±1.4 
3163 102 M 363000 156 43.0 
3461 96 F 223333 189 84.6 
3467 96 M 671667 256 38.1 
Msh6-/-
Rrm2Tg 
3677 95 F 263333 145 55.1 
55.2±20.9 
3321 102 F 352000 128 36.4 
3749 96 F 290000 176 60.7 Msh6
-/-
p53R2Tg 3751 96 F 315000 204 64.8 
54.0±15.4 
NOTE: Genomic DNA was isolated from the lungs of 3-month old mice and l vector 
was then packaged into phage. The number of mutants was derived from raw counts 
of mutant plaques.  
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frequency in Msh6-/-Rrm2Tg (55.2 ± 20.9 x 10-5) and Msh6-/-p53R2Tg (54.0 ± 15.4 x 10-
5) lung tissues was consistently higher than that in Msh6-/- lung tissue (31.1 ± 10.4 x 
10-5), although these differences were not statistically significant. By contrast, the 
mutation frequency was similar in spleen tissue from Msh6-/-Rrm2Tg (52.0 ± 20.1 x 10-
5) and Msh6-/- (50.5 ± 16.3 x 10-5) mice, but slightly elevated in Msh6-/-p53R2Tg (63.7 
± 10.7 x 10-5) animals (Fig. 2.6B and Table 2.8). Together, these results indicate that 
MMR deficiency synergizes with RNR overexpression in a tissue specific manner to 
increase mutagenesis and carcinogenesis. 
 
2.4.5     RNR-induced lung neoplasms display a unique signature of K-ras    
             activating mutations. 
A mutagenic mechanism implies that RNR overexpression triggers additional 
genetic alterations while promoting tumor development. Because mutations in codons 
12 and 61 of the K-ras proto-oncogene are often observed in human and mouse lung 
cancers (Mills et al., 1995; You et al., 1989), we examined the frequency of K-ras 
mutations in microdissected lung neoplasms from the RNR cohort. 100% of Rrm2-
induced lung neoplasms and 79% of p53R2-induced lung neoplasms carried K-ras 
activating mutations (Table 2.9), indicating that RNR-induced lung carcinogenesis 
frequently involves K-ras activating mutations. 56% and 100% of the rare lung 
neoplasms from transgene-negative control and Rrm1Tg mice, respectively, also had K-
ras mutations. 
Sequence analysis revealed that the lung neoplasms from Rrm2Tg and p53R2Tg 
mice exhibited distinct mutation spectra relative to those from transgene-negative and 
Rrm1Tg mice (Table 2.10). In particular, 50% of the K-ras codon 12 mutations from 
Rrm2-induced lung neoplasms were G→T transversions (GGT→GTT, G12V), as 
were 30% of those from p53R2-induced lung neoplasms. By contrast, lung neoplasms  
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Table 2.8. Analysis of mutation frequencies at the cII locus of a bacteriophage l 
transgene in  spleen tissue from Msh6-/- RNRTg and control mice 
NOTE: Genomic DNA was isolated from the spleen of 3-month old mice and λ vector 
was then packaged into phage. The number of mutants was derived from raw counts of 
mutant plaques.  
Stain Animal ID 
Age 
(day
s) 
Sex 
Total 
number of 
plaques 
Number 
of 
mutants 
Mutatio
n 
frequenc
y 
Mutation 
frequency 
(Avg ± SD) 
6378 90 F 173844 8 4.6 
6394 98 M 599500 24 4.0 WT 
4020 101 M 108333 3 2.8 
3.8 ± 0.9  
6380 90 F 292230 5 1.7 
6468 102 M 270000 25 9.3 Rrm1Tg 
6470 102 M 373000 14 3.8 
4.9 ± 3.9 
6395 98 M 225500 13 5.8 
6397 98 M 198000 11 5.6  Rrm2Tg 3463 96 M 226667 12 5.3 
5.6 ± 0.3 
3754 96 M 335000 9 2.7 
3378 91 F 350000 20 5.7  p53R2Tg 6790 92 F 165000 8 4.8 
4.4± 1.5 
3676 95 F 261750 78 29.8 
3750 96 F 111000 65 58.6 
2431 100 M 135000 91 67.4 Msh6
-/- 
3752 96 M 216667 100 46.2 
50.5 ± 16.3 
3163 102 M 335000 114 34.0 
3461 96 F 116000 45 38.8 
3467 96 M 149667 117 78.2 
Msh6-/-
Rrm2Tg 
3677 95 F 198333 113 57.0 
52.0 ± 20.1 
3321 102 F 138350 80 57.8 
3749 96 F 136667 104 76.1 Msh6
-/-
p53R2Tg 3751 96 F 141667 81 57.9 
63.7 ±10.7 
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Table 2.9. Mutations in K-ras codons 12 and 61 in lung tumors from RNR transgenic 
mice 
NOTE: DNA was extracted from lung neoplasm tissue isolated by laser 
microdissection. K-ras exons 1 and 2 were amplified by PCR and then directly 
sequenced.  
 
†WT FVB refers to transgene-negative control mice. 
# of mutations in K-ras 
Mouse 
genotype 
# of 
neoplasms 
analyzed  Codon 12 (%) Codon 61 (%) Total (%) 
WT FVB† 9 2 (22%) 3 (33%) 5 (56%) 
Rrm1Tg 4 4 (100%) 0 (0%) 4 (100%) 
Rrm2Tg 12 6 (50%) 6 (50%) 12 (100%) 
p53R2Tg 14 7 (50%) 4 (29%) 11 (79%) 
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Table 2.10. Mutational spectrum at K-ras codons 12 and 61 in RNR-induced 
and control lung neoplasms 
Genotype Tumor 
ID 
Mutations in codon 12 Mutations in codon 61 
1234 G12D, GGT>GAT None 
4738 G12D, GGT>GAT None 
3427 None Q61R, CAA>CGA 
3855 None Q61R, CAA>CGA 
1579 None Q61R, CAA>CGA 
3352 None None 
4741 None None 
1417 None None 
WT FVB 
(N=9) 
1575 None None 
4737 G12D, GGT>GAT None 
5804 G12D, GGT>GAT None 
984 G12D, GGT>GAT None 
Rrm1Tg 
(N=4)  
1416 G12D, GGT>GAT None 
6956 G12D, GGT>GAT None 
791 G12D, GGT>GAT None 
1577 G12V, GGT>GTT None 
5485 G12R , GGT>CGT None 
792 G12V, GGT>GTT None 
1164 G12V, GGT>GTT None 
1162 None Q61R, CAA>CGA 
1166 None Q61R, CAA>CGA 
1161 None Q61H, CAA>CAT 
6071 None Q61H, CAA>CAT 
1322 None Q61L, CAA>CTA 
Rrm2Tg 
(N=12) 
3892 None Q61L, CAA>CTA 
3114 G12D, GGT>GAT None 
1233 G12D, GGT>GAT None 
3428 G12D, GGT>GAT None 
3432 G12D, GGT>GAT None 
908 G12R, GGT>CGT None 
909 G12V, GGT>GTT None 
905 G12V, GGT>GTT None 
4817 None Q61R, CAA>CGA 
3117 None Q61R, CAA>CGA 
3353 None Q61R, CAA>CGA 
1225 None Q61H, CAA>CAT 
904 None None 
3113 None None 
p53R2Tg 
(N=14) 
907 None None 
NOTE: DNA was extracted from lung neoplasm tissue isolated by laser 
microdissection. K-ras exons 1 and 2 were amplified by PCR and then directly. 
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 from transgene-negative and Rrm1Tg mice showed exclusively G→A transitions 
(GGT→GAT, G12D) in K-ras codon 12. We conclude that K-ras activating 
mutations, common events in lung carcinogenesis, are central to Rrm2- and p53R2-
induced lung carcinogenesis and arise through a mechanism that appears distinct from 
that underlying spontaneous lung tumor development in wild-type animals. 
Alterations in the p53 tumor suppressor gene are also common in human lung cancer 
(Chiba et al., 1990). The majority of these alterations are missense mutations that 
result in the accumulation of high levels of mutant p53 protein. Other mutations in p53 
gene confer the loss of p53 expression. To investigate whether aberrant expression of 
p53 is associated with these RNR-induced lung neoplasms, we analyzed p53 
expression levels in lung neoplasms by western blotting. As shown in Fig 2.7, there 
was no difference in p53 expression levels in these RNR-induced lung neoplasms 
compared to normal lung from RNRTg or transgene negative control mice. This result 
suggests that p53 mutations may not be a common event in RNR-induced lung 
tumorigenesis. 
 
2.5 Discussion 
RNR enzyme activity has long been positively correlated with cancer cell 
division (Elford et al., 1970), and RNR inhibition is an effective strategy for 
suppressing tumor proliferation and survival (Shao et al., 2006). Yet, investigation of 
the effects of RNR deregulation in animal models has been incomplete. We report that 
overexpression of Rrm2 or p53R2 specifically induces lung but not other neoplasms at 
high frequency in transgenic mice. Previous studies indicated that human RRM2 has 
transforming activity in cultured cells (Fan et al., 1996), while p53R2 has been 
suggested to have tumor suppressor activity based on its regulation by p53 and its role 
in the DNA damage response (Tanaka et al., 2000). RNR may be an example of a  
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Figure 2.7 p53 expression in RNR-induced lung neoplasms. Western blotting analysis 
of p53 expression in lung neoplasms (Tumor 1, Tumor 2) or normal lung tissues 
(lung) from RNR transgenic mice as well as normal lung from wild-type FVB mice 
(WT FVB). Total protein was subjected to immunoblotting with antibody specific to 
p53 or α-tubulin as loading control. 
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growth regulator that has dual roles both as a tumor suppressor and oncogene. While 
impaired RNR function can trigger genomic instability by limiting nucleotide 
availability for DNA replication and repair purposes, RNR hyperactivity may be 
equally detrimental due to its mutagenic effects. Interestingly, the genomic regions 
containing human RRM2 (2p25-2p24) and p53R2 (8q23.1) are commonly amplified in 
human lung cancers (Goeze et al., 2002; Lui et al., 2001; Pei et al., 2001; Wong et al., 
2003), raising the possibility that RNR deregulation might have a causative role in 
human lung carcinogenesis.  Because RNR is a DNA damage-inducible enzyme, our 
results also suggest that increased RNR levels due to chronic DNA damage in the 
lungs of smokers may contribute to tumor development. 
In contrast to Rrm2Tg and p53R2Tg mice, Rrm1Tg mice did not show increased 
lung carcinogenesis. In addition,  Rrm1TgRrm2Tg and Rrm1Tgp53R2Tg mice did not 
show enhanced lung carcinogenesis compared to Rrm2Tg and p53R2Tg mice. This 
might be due to the relatively limited overexpression of the Rrm1 transgene. or the fact 
that the R2 subunit is the limiting component of the enzyme (Engstrom et al., 1985; 
Mann et al., 1988). However, Rrm1 demonstrates tumor suppressor activity both in 
cultured cells and human lung cancer patients (Fan et al., 1997; Gautam et al., 2003; 
Zheng et al., 2007). Consistent with our findings, Rrm1 overexpression in another 
mouse model also did not result in any overt spontaneous phenotypes and instead was 
reported to suppress chemical carcinogenesis in the lung (Gautam and Bepler, 2006). 
Thus, lung tumor induction might be specific to the small RNR subunit and 
independent of RNR enzyme activity.  
We determined that RNR-induced lung tumorigenesis proceeded through a 
mutagenic mechanism. Overexpression of Rrm2 or p53R2, but not Rrm1, in 3T3 cells 
resulted in a significant increase in mutation frequency. Additional experiments in 
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budding yeast indicated that MMR normally corrects base mispairs that arise due to 
RNR deregulation, as multiplicative increases in mutation rate were observed when 
the allosteric site mutant rnr1-D57N was combined with MMR gene mutations. A 
similar genetic interaction between RNR and MMR was observed in mice. Msh6-null 
mice develop primarily lymphoma (Edelmann et al., 1997), and p53R2 overexpression 
cooperated with Msh6-deficiency to cause an earlier onset of lymphomagenesis and 
shortened lifespan in Msh6-/-p53R2Tg mice as compared to Msh6-/- controls. We also 
observed that Msh6 deficiency strongly accelerated Rrm2-induced lung 
carcinogenesis, with 100% of Msh6-/-Rrm2Tg mice developing lung neoplasms by 6 
months of age. The accelerated lung carcinogenesis in Msh6-/-Rrm2Tg mice was 
associated with increased mutation frequency in lung tissue, while the accelerated 
lymphomagenesis in Msh6-/-p53R2Tg mice correlated with a modestly elevated 
mutation frequency in spleen tissue. The synergy observed between these pathways 
raises the possibility that aberrant RNR expression may be selected for in MMR-
deficient cancers.   
A key question arising from this study is the molecular basis for mutagenesis 
and lung tumor induction by Rrm2 and p53R2 overexpression. One possibility is that 
increased RNR expression leads to dNTP level alterations that impair replication 
fidelity and trigger mutations in growth regulatory genes. Abnormal nucleotide levels 
result in increased base misinsertion during DNA replication as well as decreased 
proof-reading due to enhanced polymerization rates (Mathews, 2006). Consistent with 
the notion that regulators of nucleotide biosynthesis can influence cell transformation, 
overexpression of another enzyme involved in dNTP biosynthesis, thymidylate 
synthase, transforms cultured cells (Rahman et al., 2004) and promotes tumor 
formation in transgenic mice (Chen et al., 2007a).   
Alternatively, carcinogenesis due to R2 subunit overexpression could be 
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independent of nucleotide metabolism. One possibility is that free radical production 
by Rrm2 and p53R2 contributes to cell transformation. During each catalytic cycle the 
small RNR subunit generates a tyrosyl radical that normally is transferred to the active 
site in Rrm1 for use in NDP reduction (Nordlund and Reichard, 2006). R2 protein 
overexpression might lead to increased radical generation and the formation of 
reactive oxygen species (ROS), which cause oxidative DNA damage and are 
mutagenic. ROS also have mitogenic effects and can play a direct role in neoplastic 
transformation (Droge, 2002). Notably, human RRM2 protein generates ROS in vitro, 
although recombinant p53R2 was reported in the same study to have antioxidant 
activity, despite the fact that both RRM2 and p53R2 generate tyrosyl free radicals 
(Xue et al., 2006). G→T transversions, a signature of oxidative DNA damage, were 
detected at K-Ras codon 12 in lung neoplasms from Rrm2Tg and p53R2Tg mice, and 
also at the Hprt locus in Rrm2 and p53R2 overexpressing 3T3 cells.  Because MMR 
corrects mismatches arising from both replication errors (Modrich, 2006) and 
oxidative DNA damage (Slupphaug et al., 2003), the multiplicative increases in 
mutagenesis and carcinogenesis observed when combining RNR overexpression with 
MMR deficiency are compatible with both dNTP level alterations and increased ROS 
production as possible mechanisms of action. 
The possibility that R2 subunit overexpression induces mutagenesis and 
tumorigenesis through excessive free radical production may account for the 
observation that RNR transgenic mice, despite broad RNR overexpression, develop 
lung but not other neoplasms at high frequency. The lung is an oxygen-rich 
environment with a high basal level of ROS (Rahman, 2003) and thus may be more 
susceptible to increased free radical production. Alternatively, it could be that the 
mutational targets of RNR dictate the tissue specificity. Indeed, activated K-ras 
preferentially induces lung neoplasms in mice (Johnson et al., 2001). Other more 
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trivial explanations for the lung specific carcinogenesis, such as subtle transgene 
expression level differences or varying DNA repair efficiencies among tissues, also 
cannot be ruled out. 
Although Rrm2 and p53R2 encode related R2 proteins, they did not give 
identical results in our experiments. While overexpression of either was capable of 
inducing lung neoplasms, Rrm2 overexpression elicited larger and more malignant 
tumors. p53R2 overexpression, on the other hand, significantly accelerated 
lymphomagenesis in Msh6-null mice, suggesting a broad effect of p53R2 
overexpression. Rrm2 also was more mutagenic than p53R2 in cultured cells, and 
induced a greater proportion of G→T transversions in both the Hprt and K-ras genes. 
One possible explanation for the partially distinct phenotypes associated with Rrm2 
and p53R2 is that both dNTP alterations and ROS production can contribute to 
neoplastic transformation, and that these activities differ between Rrm2 and p53R2. 
The distinct subcellular localizations of Rrm2 and p53R2 (Nakano et al., 2000; Tanaka 
et al., 2000) could contribute to such differing effects on dNTP biosynthesis or ROS 
production. 
Mouse models hold great promise for facilitating the development of 
diagnostic tools, prognostic markers, and therapeutics for lung cancer, the leading 
cause of cancer death world-wide. Like human lung adenocarcinomas (Linnoila et al., 
1992), the RNR-induced lung neoplasms expressed SP-C, a marker of type II alveolar 
cells. Furthermore, RNR-induced lung neoplasms arose with moderate latency in a 
stochastic process associated with an elevated mutation rate, suggesting that this may 
be a particularly authentic model for lung cancer. A mutagenic mechanism for RNR-
induced lung carcinogenesis implies that several genetic alterations are required for 
lung carcinogenesis. Consistent with this model, we observed activating K-ras 
mutations at very high frequency in RNR-induced lung neoplasms. K-ras has been 
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reported to be mutated in 90% of mouse lung neoplasms and as many as 25% of 
human lung adenocarcinomas (Mills et al., 1995; You et al., 1989). That G→T 
transversions in K-ras codon 12 were detected in RNR-induced lung neoplasms 
further validates this lung cancer model, as G→T transversions are the most common 
mutations at K-ras codon 12 in human lung cancers and correlate with a poorer 
prognosis (Keohavong et al., 1996; Rodenhuis et al., 1988). Continued use of the RNR 
lung cancer model has great potential for revealing additional genetic alterations that 
contribute to lung tumor initiation and progression. 
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CHAPTER 3 
 
RNR-induced Mutagenesis and Lung Tumorigenesis through an 
Oxidative Mechanism 
 
3.1 Abstract 
Ribonucleotide reductase plays a central role in maintaining genomic stability 
by catalyzing the rate-limiting step of dNTP biosynthesis for DNA replication and 
repair. Its activity is tightly regulated through allosteric mechanism and control of 
expression levels throughout the cell cycle. Recent studies showed that overexpression 
of the small subunit of RNR promoted lung tumorigenesis through a mutagenic 
mechanism and established a novel oncogenic activity for RNR. We initially 
hypothesized that RNR-induced mutagenesis and carcinogenesis might be caused by 
altered dNTP pools due to increased RNR activity. However, RNR-induced 
mutagenesis was not associated with altered dNTP levels or ratios.  In addition, RNR 
overexpression was not associated with acute transforming activity, which has been 
suggested by previous studies. Alternatively, we hypothesized that excess free radical 
production by the small RNR subunit may result in mutation accumulation and 
account for lung specific tumorigenesis. Indeed, Rrm2 overexpression was associated 
with elevated reactive oxygen species (ROS) levels. Rrm2 mutants, defective for RNR 
enzyme activity but still capable of producing free radicals, were able to promote 
mutagenesis and enhance ROS production. Our data indicate that the mechanism of 
RNR-induced mutagenesis and lung tumorigenesis may be independent of RNR 
enzyme activity and instead may be caused by increased oxidative stress associated 
with overexpression of the small radical generating RNR subunit. 
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3.2 Introduction 
Cancer arises due to stepwise accumulation of mutations that produce 
oncogenes with dominant gain of function and tumor suppressor genes with recessive 
loss of function. Therefore, genomic instability, due to either aging or inherited 
defects in carekeeper genes, has been thought to be the driving force of aggressive 
transformation of normal cells into highly malignant cancer cells. To maintain the 
integrity of the genome, cells employ multi-level safeguards: DNA replication, gene 
transcription, DNA repair, and cell cycle checkpoints (Hoeijmakers, 2001). Among 
these mechanisms, maintaining homeostasis of deoxyribonucleotide (dNTP) levels is 
fundamental for ensuring the replication fidelity and efficient repair of DNA lesions. 
Ribonucleotide reductase (RNR) is an essential enzyme that controls the homeostasis 
of dNTP levels and thereby maintains genomic integrity.   
RNR catalyzes the rate-limiting step in the production of deoxyribonucleotide 
triphosphates (dNTPs) for DNA replication and DNA repair. Mammalian RNR is 
composed of two non-identical homodimeric subunits: the large subunit R1 and the 
small subunit R2 (Nordlund and Reichard, 2006).  The R1 subunit contains allosteric 
regulation and catalytic sites to provide sufficient and balanced dNTP pools; the R2 
subunit contains a dinuclear iron center and a tyrosyl free radical that is essential for 
enzyme catalytic activity. A proton-coupled electron transfer chain composed of 
hydrogen-bonded residues is responsible for radical transfer between the tyrosyl 
radical site of R2 and the catalytic site of R1. In mammals, the Rrm1 gene encodes the 
large subunit R1, and the Rrm2 gene encodes the small subunit R2 which together 
form the Rrm1-Rrm2 complex that provides dNTPs for normal cell proliferation 
during S phase. The p53R2 gene encodes another small subunit and forms the Rrm1-
p53R2 complex that supplies dNTPs for mitochondrial DNA replication and DNA 
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repair throughout the cell cycle (Nakano et al., 2000; Pontarin et al., 2007; Tanaka et 
al., 2000).  
Due to its essential role in maintaining genome integrity, RNR activity is 
tightly regulated through allosteric mechanism and control of expression levels 
throughout the cell cycle (Bjorklund et al., 1990; Chabes and Thelander, 2000; 
Chabes et al., 2003b; Elledge et al., 1993). The Rrm1 protein level is constant and in 
excess throughout the cell cycle, whereas Rrm2 is limiting and only expressed during 
the S phase owing to transcriptional induction in the late G1 phase and degradation by 
Cdh-APC ubiquitination during the G2/M phase. p53R2 is expressed at a low level 
throughout the cell cycle and is induced after DNA damage in a p53 dependent 
manner (Nakano et al., 2000; Tanaka et al., 2000).   
Deregulation of RNR has been found to cause genomic instability in both yeast 
and cultured mammalian cells (Caras and Martin, 1988; Chabes et al., 2003a; 
Reichard et al., 2000). In yeast, upregulation of RNR by abolishing feedback 
inhibition at the activity site of R1 subunit leads to improved survival after DNA 
damage and increased mutagenesis associated with altered dNTP pools (Chabes et al., 
2003a; Zhao et al., 1998). In cultured mammalian cells, deregulation of RNR by 
mutating the activity site responsible for feedback inhibition resulted in increased 
mutagenesis, although no dNTP pool alterations were detected (Caras and Martin, 
1988). Recently, we generated mouse models of RNR deregulation and identified a 
novel causative role of RNR in the etiology of spontaneous lung neoplasms through a 
mutagenic mechanism (Xu et al., 2008). Overexpressing the small subunits of RNR, 
Rrm2 and p53R2, is mutagenic in cultured 3T3 cells and in transgenic mouse tissues. 
More strikingly, widespread overexpression of the small subunit of RNR in 
transgenic mice specifically promotes lung carcinogenesis. Studies in human cancers 
suggest that RRM1 is a putative tumor suppressor gene (Pitterle et al., 1999) and loss 
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of heterozygosity at the chromosome region containing RRM1 has been correlated 
with poor survival in non-small cell lung cancer patients (Bepler et al., 2002). 
However, RRM1 overexpression has been linked to drug resistance in tumor 
chemotherapy, and is utilized as a marker for chemoresistance and poor survival in 
patients with advanced NSCLC (Ceppi et al., 2006; Gazdar, 2007). Thus, RRM1 in 
NSCLC has been proposed to have a dual role in both cancer susceptibility and drug 
resistance (Gazdar, 2007). There is limited information concerning the effect of 
RRM2 expression in tumors. Overexpression of RRM2 in human oral carcinoma cells 
enhanced invasive potential (Zhou et al., 1998b). Polymorphisms of the p53R2 gene 
have also been found to correlate to esophageal squamous cell carcinomas and colon 
carcinoma. More interestingly, the genome regions containing human RRM2 and 
P53R2 are frequently amplified in lung cancer patients (Goeze et al., 2002; Lui et al., 
2001; Pei et al., 2001). 
Studies in human patients and our RNR transgenic mouse model may provide 
new insights into the role of RNR in cancer development. Rather than functioning 
only as a downstream effector of transformation by providing high dNTP levels for 
cancer cell proliferation, RNR deregulation also may have a direct role in initiation of 
cancer development by promoting mutagenesis, leading to mutations in oncogenes or 
tumor suppressor genes. However, the molecular mechanisms of RNR-induced 
mutagenesis and lung tumorigenesis are still unclear.   
The simplest explanation for RNR-induced mutagenesis is that deregulation of 
RNR causes altered dNTP pools, which are mutagenic. Mutagenesis induced by RNR 
deregulation in budding yeast is associated with altered dNTP levels (Chabes et al., 
2003a).  However, there has been conflicting reports on whether altered dNTP levels 
are associated with mutagenesis caused by RNR deregulation in mammalian cells 
(Caras and Martin, 1988; Weinberg et al., 1981). One possible explanation for this 
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discrepancy is that changes in dNTP levels in subnuclear compartments are 
undetectable by measurement of total dNTP levels. Alternatively, other mechanisms 
that control dNTP homeostasis, such as the control of enzymes in the salvage 
pathway, may play a role in keeping dNTP levels undisturbed when RNR is 
deregulated. It also remains possible that RNR-induced mutagenesis could be 
independent of RNR enzyme activity. 
Previous studies suggest that Rrm2 has transforming activity since Rrm2 can 
enhance transforming potential in combination with activated oncogenes in cultured 
mammalian cells.  However, Rrm2 alone has not been found to have any direct 
transforming activity (Fan et al., 1998; Fan et al., 1996). Interestingly, p53R2 has 
previously been suggested to have tumor suppressor activity, since it is induced 
transcriptionally after DNA damage in a p53 dependent manner. p53R2 directly 
participates in DNA damage repair by providing dNTPs and p53R2 deficient cells are 
more sensitive to DNA damage agents (Nakano et al., 2000; Tanaka et al., 2000). 
However, p53R2 transgenic mice were also highly prone to spontaneous lung 
tumorigenesis and cells overexpressing p53R2 exhibited enhanced mutagenesis (Xu 
et al., 2008).  Thus, the role of p53R2 in genomic stability and cancer is still unclear.  
Since the small subunit of RNR contains a tyrosyl radical essential for enzyme 
activity, another potential mechanism for RNR-induced mutagenesis and lung 
carcinogenesis is that free radical production due to the overexpressed small subunit 
and leads to oxidative DNA damage that drives RNR-induced mutagenesis and 
carcinogenesis. Recently, studies found that human RRM2 recombinant protein can 
function as an oxidant reagent due to its ability to produce free radicals (Xue et al., 
2006), although p53R2 has been proposed to have anti-oxidative property, despite the 
fact that both RRM2 and p53R2 generate tyrosyl radicals. ROS generating property of 
human RRM2 raises the possibility that elevated RNR expression might cause 
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increased oxidative stress, leading to genomic instability and lung cancer 
development.  
There has been abundant evidence for involvement of ROS in lung 
carcinogenesis in both human lung cancer studies and mouse lung cancer models.  It 
is well known that tobacco smoke contains DNA oxidants and causes an increase in 
8-oxo-deoxyguanine (8-oxo-dG) in the human lung. 8-oxo-dG is the most prevalent 
oxidative DNA damage, and can base pair with adenine and cytosine with equal 
efficiency during DNA replication, resulting in G to T transversions (Nakabeppu et 
al., 2004).  Lung cancer patients had higher levels of 8-oxo-dG than in non-lung 
cancer patients (Inoue et al., 1998). Lung cancer risk is reduced by consumption of 
anti-oxidant containing fruits and vegetables (Miller et al., 2004; Riboli and Norat, 
2003). Increased levels of MnSOD and decreased levels of catalase, two key players 
in regulation of intracellular ROS levels, have been found in human lung cancer 
patients. A polymorphic variant in OGG1, a protein that excises 8-oxo-dG from 
DNA, causes reduced enzyme activity and the increased risk of lung cancer (Le 
Marchand et al., 2002). Mth1 hydrolyzes the 8-oxo-dGMP, avoiding the incorporation 
of 8-oxo-dG into DNA during DNA synthesis, and Ogg1 glycosylase removes 8-oxo-
dG from DNA (Nakabeppu et al., 2004).  In mouse models, deficiency in either the 
Ogg1 gene or the Mth1 gene in knockout mice is associated with an increased 
incidence of lung tumors. Ogg1 knockout mice accumulated high levels of 8-oxo-dG 
(Minowa et al., 2000; Sakumi et al., 2003; Tsuzuki et al., 2001; Xie et al., 2004). This 
evidence supports ROS as a causative agent in lung cancer development (Maciag and 
Anderson, 2005).  
We previously found that widespread overexpression of RNR in transgenic 
mice specifically promotes spontaneous lung tumorigenesis through a mutagenic 
mechanism (Xu et al., 2008). Notably, we found increased signature mutations of 
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oxidative DNA damage at K-ras codon 12 from these RNR-induced lung neoplasms 
and at the Hprt gene locus in RNR overexpressing 3T3 cells. Mismatch repair 
corrects mismatches from replication error and oxidative DNA damage (Modrich, 
2006; Slupphaug et al., 2003). We observed multiplicative increase in mutagenesis 
and lung tumorigenesis when combining RNR overexpression with mismatch repair 
deficiency in our previous study, a finding that is compatible with increased ROS 
production as possible mechanism for RNR-induced mutagenesis. The lung is an 
oxygen-rich environment with high basal level of ROS (Rahman, 2003) and thus may 
be more susceptible to free radical production. This evidence strongly suggests that 
RNR-induced lung tumorigenesis might involve oxidative DNA damage in a highly 
tissue specific manner. This may be related to the redox property of the small subunit 
of RNR.  
In this study, we investigated the molecular mechanisms of RNR-induced 
mutagenesis and lung tumorigenesis and obtained results suggesting that RNR 
overexpression drives mutagenesis and lung tumorigenesis through an oxidative 
mechanism. First, we did not observe detectable alterations in dNTP levels or ratios in 
lung cells from RNR transgenic mice or in RNR overexpressing 3T3 cells. Second, 
we did not observe acute transforming activity of RNR. However, Rrm2 
overexpressing cells consistently show increased ROS levels. Interestingly, cells 
overexpressing Rrm2 mutants, which are defective for RNR enzyme activity but can 
still produce the initial tyrosyl radical or a transient tryptophan radical, exhibited 
enhanced mutagenesis and increased oxidative stress. Our results indicate that RNR-
induced mutagenesis may be independent of RNR enzyme activity, and instead could 
act through elevated oxidative stress due to free radical overproduction.  
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3.3 Materials and Methods 
3.3.1 Cells. 
All cells were cultured in culture medium (Dulbeco’s Modification of Eagles 
Medium supplemented with 10% bovine calf serum, 1.0 mM L-glutamine, 0.1 mM 
MEM non-essential amino acids, 100 µg/ml of streptomycin sulfate, and 100 U/ml of 
penicillin). Mouse 3T3 cells overexpressing Rrm1, Rrm2, p53R2, Rrm2-Y177W, 
Rrm2-Y370W, Rrm2-Y177F, Rrm2-Y370F, or empty vector were generated as 
described in Material and Methods section in Chapter 2. 
 
3.3.1 Measurement of intracellular dNTP pool size. 
106 RNR over-expressing 3T3 cells were plated on 100mm tissue culture 
dishes in DMEM supplemented with 10% dialyzed bovine calf serum on the day 
before the experiment. 24 h after plating, cells were harvested by trypsinization and 5x 
105 cells were centrifuged for 3 min at 1300g. The supernatant was aspirated and the 
cell pellet was extracted with 100 µl of cold 0.4N perchloric acid for 20 min on ice. 
After centrifugation (1 min at 16,000g), the supernatant was neutralized by mixing 
with 100 µl 0.5N trioctylamine (Sigma) in 1, 1, 2-trichlorotrifluoroethane (Sigma). 
The phases were separated by centrifugation (2 min at 16,000g) and the upper aqueous 
phases were fast frozen in dry ice-ethanol and stored at –80°C until analyzed. dNTP 
pool size was measured according to methods described by Sherman and Fyfe 
(Sherman and Fyfe, 1989).  The reaction mixture (40 µl) contained 100mM HEPES 
buffer (pH 7.3) and 10mM MgCl2, 1 U of E. coli DNA polymerase I  klenow fragment 
(Fermentas), 0.25µM (for dATP and dTTP) or 0.05µM (for dCTP or dGTP) 
oligonucleotide template, 8 µl of dNTP extract, and 1.25 µM 3H-dATP(18 Ci/mmol, 
Moravek Biochemicals) (for dTTP, dCTP, and dGTP) or 3H-dTTP(60 Ci/mmol, 
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Moravek Biochemicals) ( for dATP). Following is the sequence of oligonucleotide 
template for measuring:  
dTTP:5'ATTATTATTATTATTAGGCGGTGGAGGCGG 3' 
3' CCGCCACCTCCGCC 5' 
dCTP:5' TTTGTTTGTTTGTTTGTTTGGGCGGTGGAGGCGG 3' 
3' CCG CCACCTCCGCC 5' 
dGTP:5' TTTCTTTCTTTCTTTCTTTCGGCGGTGGAGGCGG 3' 
3' CCGCCACCTCCGCC 5' 
dATP:5' AAATAAATAAATAAATAAATGGCGGTGGAGGCGG 3' 
3'CCGCCACCTCCGCC 5' 
Reactions were started by addition of the enzyme and were carried out for 60 min at 
room temperature. After incubation, 20 µl aliquots were removed and spotted onto 
Whatman DE81 paper. The papers were dried, washed (3x 10 min) with 5% Na2HPO4, 
and rinsed once each with distilled water and 95% ethanol. After drying, the 
radioactivity on the paper was measured in a liquid scintillation counter. 
 
3.3.2 Lung cell isolation and preparation. 
3-month old wildtype FVB, Rrm1, Rrm2 and p53R2 transgenic mice were 
euthanized and lung cells were isolated. Briefly, perfused and lavaged lungs were 
digested with elastase  (4.3U/ml, Worthington, Lakewood, NJ) for 25 min at 37°C, 
then minced sequentially filtered through nylon meshes (160, 37, 10µm pore size), and 
plated on mouse IgG  (Polysciences, Inc ) coated cell culture dishes for 1h at 37°C in a 
humidified incubator with 6% CO2 in air (Bates et al., 2002). Cells were then 
trypsinized and harvested for dNTP measurement. To make IgG coated plates, put 1.5 
ml 0.5mg/ml IgG in 50mM Tris (pH=9.5) to cover 60mm culture dish and rock for 3 
hrs at room temperature. 
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3.3.4 Focus formation assay. 
1x106 3T3 cells were plated on 100mm dishes with DMEM supplemented with 
10% bovine calf serum the day before the experiment. 24 hrs later, cells were fed with 
fresh DMEM supplemented with 10% bovine calf serum. Cells were then transfected 
by calcium phosphate precipitation using 20µg of each construct plasmid DNA. 48 hrs 
post transfection, cells were trypsinized and 1/3 of cells were passed into new 100mm 
cultured dishes and fed with DMEM supplemented with 10% bovine calf serum every 
3 days for 3 weeks. Cells were then fixed in 95% methanol for 1 h, stained with 10% 
Giemsa, and foci were scored. Ras and Myc plasmids have been described previously 
(Kelekar and Cole, 1987; Parada et al., 1982). 
 
3.3.5 Construction of expression plasmids and site-directed mutagenesis.  
Rrm2-Y177W, Rrm2-Y177F, Rrm2-Y370W and Rrm2-Y370F mutant 
constructs were generated by overlap extension PCR of pCaggs-Rrm2 plasmid where 
the required mutation was introduced as described previously (Ho et al., 1989). The 
internal primers that hybrids at the site of mutations for site-directed mutagenesis 
were:  
Y177W forward: 5’-
GGAAAACATACACTCTGAAATGTGGAGTCTCCTTATTGACACTTAC-3’; 
Y177W reverse: 5’-
GTAAGTGTCAATAAGGAGACTCCACATTTCAGAGTGTATGTTTTCC-3’; 
Y370W forward: 5’-GCGAGTAGGCGAGTGGCAGAGGAGGGGAGTCATG-3’; 
Y370W reverse: 5’-CATGACTCCCATCCTCTGCCACTCGCCTACTCGC-3’;  
Y177F forward: 5’-
GGAAAACATACACTCTGAAATGTTCAGTCTCCTTATTGACACTTAC-3’; 
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Y177F reverse: 5’-
GTAAGTGTCAATAAGGAGACTGAACATTTCAGAGTGTATGTTTTCC-3’; 
Y370F forward: 5’-TTGAGAAGCGAGTAGGCGAGTTTCAGAGGATGG-3’; 
Y370F reverse: 5’-CCATCCTCTGAAACTCGCCTACTCGCTTCTCAA -
3’(underlined letters denote the mutated codon); 
The upstream flanking primer containing the xhoI site used for PCR extension is: 5’-
AAACTCGAGCCATGCTCTCCGTCCGCACCCC-3’  and the downstream flanking 
primer containing the xhoI site is : 5’-
AGAGCTCGAGTTAGAAGTCAGCATCCAAGGT-3’ (boldface letters denote the 
xhoI site) ;  
To synthesize overlapping fragments, two separate PCR reactions were 
performed. In the first PCR reaction, the universal upstream flanking primer and 
reverse site-specific internal primer for each mutant were used to generate upstream 
overlapping fragment; in the second reaction, forward site-specific internal primer for 
each mutant and the universal downstream flanking primer were used to amplify 
downstream overlapping fragment. Synthesized upstream and downstream 
overlapping fragments were then fused by denaturing and annealing them in a 
subsequent extension reaction. The fused products were then PCR amplified using the 
universal upstream flanking primer and the universal downstream flanking primer. 
The fragments containing the mutations were then ligated into the pCaggs-Rrm2 
plasmid digested with xhoI to replace the original wildtype Rrm2 fragment. Whole 
Rrm2 cDNA was sequenced for all plasmids to confirm the mutated codons and to 
ensure the absence of other mutations.  
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3.3.6 Generation of mutant Rrm2 overexpressing 3T3 cell pools. 
Mouse 3T3 fibroblasts were transfected either with the empty pCaggs vector 
(1.35 µg) as a control or with the pCaggs-Rrm2, pCaggs-Rrm2-Y177W, pCaggs-
Rrm2-Y370W, pCaggs-Rrm2-Y177F, or pCaggs-Rrm2-Y370F expression vector 
(1.35 µg) along with PGK-puro (0.15 µg) using FuGENE 6 Transfection Reagent 
(Roche Diagnostics Co., Mannheim, Germany) following the procedure recommended 
by the manufacturer. The medium was replaced by selection medium containing 
1.25 µg/ml puromycin every 2 days. After 3 weeks, puromycin-resistant cells were 
pooled and expanded for further analysis under selection conditions. 
 
2.5.1 Western blot analysis.  
Cultured cells were prepared in RIPA buffer (50mM Tris-HCl [pH 8.0], 1% 
[vol/vol] Nonidet P-40, 0.5% sodium deoxycholate, 0.1% [wt/vol] sodium dodecyl 
sulfate, 150mM sodium chloride, 50mM sodium fluoride) and 1x protease inhibitor 
cocktail (Roche). Immunoblotting was performed on PVDF membranes using 
standard methods, with signal detection by enhanced chemiluminescence (Pierce). The 
antibodies used were goat anti-R2 (sc-115, Santa Cruz Biotechnology,) and α-tubulin 
(A5441, Sigma). 
 
2.5.2 Cell proliferation assay. 
Cells were cultured and passed according to the 3T3 protocol. In brief, 106 
cells were plated on a 100 mm culture dish; after 3 days, cells were counted and 106 
cells were replated. Population Doublings were calculated using the formula 
ΔPDL=log(nf/n0)/log2, where n0 is the initial number of cells and nf is the final 
number of cells at each passage(Blasco et al., 1997). 
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2.5.3 Hprt mutation rate assay. 
Cells were cultured in HAT medium (culture medium supplemented with 
0.2mM sodium hypoxanthine, 0.4µM aminopterin, 0.02µM thymidine [GIBCO]) for 
two weeks. Cells then were cultured in HT medium (culture medium supplemented 
with 0.1mM sodium hypoxanthine, 0.016µM thymidine [GIBCO]) for one week. 
Subsequently, cells were seeded at a density of 5x105 cells per 10cm plate (10 plates 
total) in culture medium containing 5µg/ml 6-thioguanine (Sigma) for 3 weeks. Then 
plates were fixed in methanol for 1 hour and stained with crystal violet overnight, then 
rinsed with water and dried. Number of 6-thioguanine resistant colonies were then 
counted. Plating efficiency was determined by plating 200 cells in medium without 6-
thioguanine in triplicate for 2 weeks and counting stained colonies (Fenwick, 1985). 
 
3.3.7 ROS measurement. 
Intracellular ROS levels were measured by quantifying carboxyl-2,7-
dichlorodihydrofluorescin diacetate ( CH3-DCFDA) fluorescence. Briefly, 1x 106 
Rrm2 over-expressing 3T3 cells were plated per 100mm tissue culture dish in DMEM 
supplemented with 10% bovine calf serum two days before the experiment. 48 hrs 
after plating, cells were trypsinized and washed twice with warm PBS. 1x 106 cells 
were then resuspended in 10µM freshly prepared CH3- DCFDA ( Molecular Probe ) at  
1x 106 cells/ml and incubated at 37°C in the dark for 20 min. Cells were then filtered 
through 40 micron nylon mesh and analyzed immediately by flow cytometry at 488 
nm excitation and 530 nm emission on a FACs-Calibur flow cytometer (Beckman). 
Ten thousands cells were routinely collected and data were analyzed with Flowjo 
software (Radisky et al., 2005).  
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3.4 Results 
3.4.1 No detectable alterations in dNTP levels or ratios in RNR overexpressing 
3T3 cells and RNR transgenic lung tissues. 
RNR deregulation by abolishing feedback inhibition at the activity site of R1 
subunit in yeast causes altered dNTP levels and enhanced mutagenesis (Chabes et al., 
2003a). We hypothesized that the mutagenic effects of RNR overexpression would 
also involve altered dNTP pool size due to an increased RNR activity, which is 
manifested by enhanced mutagenesis in RNR overexpressing cells and by lung 
tumorigenesis in RNR transgenic mice (Xu et al., 2008). To test this hypothesis, we 
first measured intracellular dNTP levels in logarithmically growing RNR 
overexpressing 3T3 cells. There were no significant differences detected in dATP, 
dTTP, dCTP and dGTP pools in Rrm1, Rrm2 and p53R2 overexpressing cells 
compared to those in empty plasmid vector cells (Fig. 3.1A). Each dNTP pool size 
was consistent with previously reported results for logarithmically growing 3T3 cells, 
with dTTP being highest and dGTP being lowest (Ke et al., 2005). To further test this 
in vivo, we analyzed intracellular dNTP levels in lung cells from 3-month old RNR 
transgenic mice. Compared to lung cells from wildtype control mice, lung cells from 
Rrm1, Rrm2 and p53R2 transgenic mice exhibited similar levels of dATP, dTTP, 
dCTP and dGTP pools (Fig. 1B). The individual dNTP levels in these adult lung cells 
were consistent with the reported dNTP levels in muscle tissue, with dCTP pool being 
highest and dTTP pool being the lowest (Hakansson et al., 2006b). In summary, RNR 
overexpression was not associated with detectable changes in dNTP levels or ratios in 
RNR overexpressing 3T3 cells and transgenic lung cells, suggesting that RNR 
overexpression induced mutagenesis and lung tumorigenesis might not involve altered 
dNTP levels or ratios.  
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Figure 3.1  Intracellular dNTP pools in logarithmically growing RNR over-expressing 
3T3 cells or RNR transgenic lung tissues. Intracellular dNTPs were extracted and 
quantified from (A) logarithmically growing 3T3 cells overexpressing Rrm1, Rrm2, 
p53R2, or containing the empty plasmid vector and (B) RNR transgenic lung tissues, 
using an enzymatic assay as described in Materials and Methods. Each data point 
represents the mean of three independent experiments, with error bars representing the 
standard deviation.
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3.4.2 RNR has no detectable acute transforming activity. 
Previous studies suggest that Rrm2 has transforming potential in cooperation 
with a variety of oncogenes (Fan et al., 1998; Fan et al., 1996). To determine whether 
lung tumorigenesis caused by Rrm2 and p53R2 overexpression involves acute 
transforming activity of the small RNR proteins, we transfected Rrm1, Rrm2, p53R2 
and control vector into 3T3 cells and scored formation of transformation foci 3 weeks 
posttransfection. As shown in Fig. 3.2.A, introduction of any of the RNR genes alone 
did not result in the focus formation, suggesting that overexpression of individual 
RNR genes is not sufficient to transform 3T3 cells, which is consistent with previous 
reports (Fan et al., 1998; Fan et al., 1996). Previous studies suggest that Rrm2 
increased focus formation in H-ras transfected 3T3 cells. To further test whether RNR 
cooperate with the H-ras gene in focus formation and explore the role of transforming 
activity in RNR-induced tumorigenesis, we introduced Rrm1, Rrm2, p53R2 and 
control vector into 3T3 cells along with H-ras gene to assess focus formation. We 
observed that Rrm1, Rrm2, and p53R2 did not cooperate with H-ras to transform 3T3 
cells, since they exhibited a similar number of foci with cells co-transfected with 
vector and H-ras (Fig 3. 2.B, C). However, consistent with previous studies that c-Myc 
can cooperate with H-ras in focus transformation, c-Myc and H-ras co-transfected 
cells exhibited significantly increased foci formation. Our data suggest that RNR-
induced lung carcinogenesis might not involve direct transforming activity of RNR. 
 
3.4.3 Generating Rrm2-Y177W and Rrm2-Y370W mutant overexpressing 3T3   
         cells. 
We did not observe altered dNTP levels and ratios in RNR overexpressing 
cells. Although cannot rule out the possibility that alterations in dNTP levels within  
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Figure 3.2. Focus formation in 3T3 cells transfected with either individual RNR genes 
or RNR genes with H-ras genes. (A) 3T3 cells were transfected with Rrm1, Rrm2, 
p53R2 or empty plasmid vector using Calcium phosphate coprecipitation methods.  
Transfected cells were fed every 3 days for 3 weeks, then fixed and stained with 
Giemsa. (B) 3T3 cells were co-transfected with H-ras gene with Rrm1, Rrm2, p53R2 
or empty plasmid vector using Calcium phosphate coprecipitation methods.  
Transfected cells were fed every 3 days for 3 weeks, then fixed and stained with 
Giemsa. Cells co-transfected with c-Myc and H-ras were used as positive control. (C) 
The number of foci formation in three independent experiments was plotted. Each data 
point is the mean with error bars representing the standard deviation. 
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Figure 3.2 (continued)
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Figure 3.2 (continued)
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subcellular compartments are undetectable when measuring total dNTP levels, our 
data suggest that mutagenic and lung tumorigenic effects caused by RNR 
overexpression might involve other RNR activities beside reduction of NDP. One such 
mutagenic activity could be radical production, since both the mutator phenotype and 
lung cancer development were specific to small subunit overexpression. We 
hypothesized that RNR induced mutagenesis and lung tumorigenesis might involve 
increased reactive oxygen species due to elevations in free radical production 
associated with small subunit overexpression. To test whether enzyme activity or free 
radical formation is required for RNR-induced mutagenesis and lung tumorigenesis, 
we generated Rrm2 mutants defective for these functions (Fig. 3.3).  
The Rrm2-Y177W mutant, with a mutation at the initial tyrosyl radical site, 
has been shown to only produce a transient tryptophan radical and to be defective for 
enzyme activity (Potsch et al., 1999). The Rrm2-Y370W mutant, carrying a mutation 
in the radical transfer path between the Rrm2 and Rrm1 subunits, can still produce the 
initial tyrosyl radical but only has a 1.7% of RNR enzyme activity compared to the 
wildtype Rrm2 protein (Rova et al., 1999). To test whether these Rrm2 mutants, which 
are unable to support RNR enzyme activity but can still produce radicals, are also 
mutagenic, we generated Rrm2-Y177W and Rrm2-Y370W mutant constructs using site-
directed mutagenesis and cloned them into the same pCaggs expression vector used 
for generating RNR overexpressing 3T3 cells and RNR transgenic mice. Then we 
generated Rrm2-Y177W mutant and Rrm2-Y370W mutant overexpressing 3T3 cell 
pools as described in Material and Methods. Overexpression of individual Rrm2 
mutant genes in these cells was confirmed by Western blot (Fig. 3.4A). The cells 
overexpressing wildtype Rrm2, Rrm2-Y177W or Rrm2-Y370W mutants had similar 
proliferation rates as compared to cells expressing empty vector (Fig. 3.4B) 
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Figure 3.3  Schematic showing Rrm2 mutants and predicted results. Rrm2 mutants 
defective for either radical production or enzyme activity were generated to assess 
their importance in RNR-induced mutagenesis. Rrm2-Y177W mutant can produce a 
transient tryptophan radical and is defective for enzyme activity. Rrm2-Y370W and 
Rrm2-Y370F mutant are unable to support enzyme activity due to a mutation at a 
residue required for radical transfer, but can still produce initial tyrosyl radical at 
Y177. Rrm2-Y177F mutant is defective for both radical generation and enzyme 
activity.  
 
 
99 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 3.4 Increased mutation frequency in Rrm2 mutant overexpressing 3T3 cell 
pools. (A) Western blot analysis of Rrm2 protein expression in 3T3 cells 
overexpressing Rrm2-Y177W and  Rrm2-Y370W mutants. Total protein was extracted 
from the indicated cell lines and subjected to immunoblotting with antibodies specific 
to Rrm2. The membrane was re-probed for α-tubulin as a loading control. (B) 
Accumulated population doublings (PDL) of 3T3 cells overexpressing Rrm2, Rrm2-
Y177W, Rrm2-Y370W or empty plasmid vector. Cells were cultured following a 3T3 
protocol as described in Material and Methods. Plot shows the number of PDL. (C) 
Mutation frequency at the Hprt locus in 3T3 cells overexpressing Rrm2, Rrm2-
Y177W, Rrm2-Y370W or empty plasmid vector. Mutation frequency was determined 
by Hprt assay as described in Material and Methods. 
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3.4.4 Increased Hprt mutation rates in Rrm2 mutant cells that are defective for   
         RNR enzyme activity. 
To test whether RNR-induced mutagenesis depends on RNR enzyme activity, 
we measured mutation frequency in Rrm2 mutant cells, defective for RNR enzyme 
activity, using the Hprt mutation detection assay.  Consistent with our previous 
results, a significantly increased mutation frequency was observed in wildtype Rrm2 
overexpressing cell pool (10.6 x 10-6) as compared to empty plasmid vector cells (1.6 
x 10-6) (Fig. 3.4C). Notably, cell pools overexpressing Rrm2-Y177W or Rrm2-Y370W 
exhibited significantly increased mutation frequencies compared to control cells. 
Mutation frequency in cells overexpressing the Rrm2-Y177W mutant was lower than 
wildtype Rrm2 overexpressing cells, but significantly higher than vector (7.6 x 10-6 
versus 1.6 x10-6).  Since Rrm2-Y177W is defective for RNR enzyme activity but can 
still produce a transient tryptophan radical, this supports a model in which RNR-
induced mutagenesis is independent of RNR enzyme activity and may instead be due 
to increased free radical production. Cells overexpressing Rrm2-Y370W showed the 
highest mutation frequency (20.5x 10-6). The initial tyrosyl radical can still be 
produced in the Rrm2-Y370W mutant, but cannot be transferred to the Rrm1 subunit 
due to defects in the radical transfer path. Therefore, the high mutation frequency 
observed in cells overexpressing Rrm2-Y370W might reflect that initial tyrosyl radical 
produced in this mutant were leaked into cells and led to oxidative damage and 
increased mutagenesis. Together, these results indicate that Rrm2-induced 
mutagenesis is independent of RNR enzyme activity, and most likely depends on its 
radical production activity. 
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3.4.5 Increased ROS levels in Rrm2 and Rrm2 mutant cells. 
To determine whether increased ROS levels account for the increased 
mutagenesis in wildtype Rrm2 overexpressing cells. We first measured the levels of 
ROS in 3T3 cells overexpressing wildtype Rrm2 using carboxyl -2’-7- 
dichlorohydrofluorescein diacetate (CH3-DCFDA) staining. CH3-DCFDA can readily 
cross cell membranes and is hydrolyzed by intracellular esterase to non-fluorescent 
carboxyl -2’-7- dichlorohydrofluorescein (CH3-DCFH) (Radisky et al., 2005). In the 
presence of ROS, CH3-DCFH is oxidized, producing highly fluorescent molecule 
carboxyl -2’-7- dichlorofluorescein (CH3-DCF). CH3-DCF fluorescence is commonly 
used as a indicator of oxidative stress. As shown in Figure 3.5A, Rrm2 overexpressing 
cells exhibited an average 2.2 fold increase in ROS levels compared to empty vector 
cells(p<0.01, t-test). Five independent Rrm2 overexpressing cell pools showed 
consistently increased ROS production. Consistent with previous reports that H-ras 
transformed 3T3 cells produce large amounts of the reactive oxygen species (Irani et 
al., 1997), H-ras transfected 3T3 cells were used as a positive control and showed a 
5.1 fold increase in ROS levels compared to vector (p<0.01, t-test). Figure 3.5B shows 
the overlay of one representive experiment for CH3-DCFDA intensity. These results 
indicate that increased ROS production contributes to Rrm2-induced mutagenesis.  
Although Rrm2-Y177W and Rrm2-Y370W mutants are defective for RNR enzyme 
activity, they can still produce a transient tryptophan radical or the initial tyrosyl 
radical, respectively. To further test whether increased mutagenesis in Rrm2-Y177W 
and Rrm2-Y370W mutant cells was due to increased ROS production, we measured 
intracellular ROS levels in cells overexpressing these mutants. As shown in Figure 
3.5C, cells overexpressing Rrm2-Y177W showed a 2.7 fold increase in ROS levels 
compared to vector cells (p<0.05 t-test), suggesting that the Rrm2-Y177W mutant 
might cause mutagenesis through radical production and a possible oxidative damage 
mechanism. Rrm2-Y370W mutant cells exhibited the highest elevations in  
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Figure 3.5. Increased reactive oxygen species levels in Rrm2 and Rrm2 mutant 
overexpressing cells. (A) Intracelluar ROS levels were assessed by FACs analysis of 
CH3-DCFDA fluorescence in Rrm2 overexpressing 3T3 cell pools. H-ras transfected 
3T3 cells used as a positive control. Each data point is the mean of 5 independent cell 
lines, with error bars representing the standard deviation. “*” symbol indicates that 
there is a statistically significant difference (p< 0.05) relative to control vector cells by 
student t –test. (B) Overlay of one representative experiment showing the distribution 
of CH3-DCFDA fluorescence. (C) Intracellular ROS levels in 3T3 cells 
overexpressing Rrm2, Rrm2-Y177W, Rrm2-Y370W or empty plasmid vector assessed 
by FACs analysis of CH3-DCFDA fluorescence. Each data point is mean of three 
independent experiments with error bars representing the standard deviations. “*” 
symbol indicates that there is a statistically significant difference (p< 0.05) relative to 
control vector cells by student t –test; “#” symbol indicates that p value is 0.051 by 
student t –test. 
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ROS production (2.9 fold increase compared to vector cells, p=0.051, t-test), which is 
in consistent with the highest Hprt mutation frequency observed in Rrm2-Y370W cells 
(Figure 3.4 C), further implicating elevated radical production, rather than increased 
RNR enzyme activity, as the major driving force of RNR-induced mutagenesis, and 
potentially, lung tumorigenesis. 
 
3.4.6 Increased ROS levels in a Rrm2 mutant that is defective for radical  
         production.  
To directly test whether free radical formation is required for RNR-induced 
mutagenesis and lung tumorigenesis, we generated two additional Rrm2 mutants to 
distinguish the role between RNR enzyme activity and radical production activity 
(Fig. 3.3). 
A second mutation at the tyrosyl radical site, in which tyrosine residue is 
replaced by non-oxidizable phenylalanine, the Rrm2-Y177F mutant, has been shown 
to suppress the radical formation and completely destroy RNR enzyme activity 
(Potsch et al., 1999). A second mutation at the tyrosine 370 residue on the radical 
transfer path between the Rrm2 and Rrm1 subunit, in which tyrosine residue is 
replaced by non-oxidizable phenylalanine, Rrm2-Y370F, has been shown to be 
complete inactive for RNR enzyme activity, but the initial tyrosyl radical at residue 
177 is intact (Rova et al., 1999). We generated Rrm2-Y177F and Rrm2-Y370F mutant 
constructs using site-directed mutagenesis and cloned them into same expression 
vector used for generating RNR overexpressing 3T3 cells and RNR transgenic mice. 
We then generated Rrm2-Y177F mutant and Rrm2-Y370F mutant overexpressing 3T3 
cell pools as described in Material and Methods. Overexpression of individual Rrm2 
mutant genes in these cells was confirmed by Western blot (Fig. 3.6A). The cells 
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overexpressing wildtype Rrm2, Rrm2-Y177F or Rrm2-Y370F mutants had similar 
proliferation rates as compared to cells expressing empty vector (Fig. 3.6B) 
 
We predicted that cells overexpressing the Rrm2-Y177F mutant would not 
have increased ROS production, but cells overexpressing Rrm2-Y370F would, if 
increased ROS production in Rrm2 overexpressing cells is dependent on radical 
production at the tyrosine Y177 site. Cells overexpressing wildtype Rrm2 again 
showed a 2.3 fold increase in ROS levels compared to vector cells (p=0.08, t-test)(Fig. 
3.6B). As we predicted, cells overexpressing Rrm2-Y370F mutant showed a 3.5 fold 
increase in ROS levels compared to that in vector cells (p<0.05, t-test). Surprisingly, 
cells overexpressing Rrm2-Y177F, defective for both enzyme activity and radical 
production, also showed increased ROS production (2.5 fold compared to vector cells, 
p<0.05, t-test). These data suggest that cells overexpressing Rrm2-Y177F mutant still 
cause increased oxidative stress, probably through other mechanisms, such as a 
dominant negative effect by binding to Rrm1 and indirectly inhibiting RNR function 
of providing dNTPs for mitochondria, causing mitochondria defect and increased 
oxidative stress. To test whether RNR-induced mutagenesis depends on the radical 
production activity, we are going to measure mutation frequency in Rrm2-Y177F 
mutant cells using Hprt mutation detection assay.  
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Figure 3.6. Increased reactive oxygen species levels in Rrm2 mutant overexpressing 
cells. (A) Western blot analysis of Rrm2 protein expression in 3T3 cells 
overexpressing Rrm2-Y177F, Rrm2-Y370F mutants. Total protein was extracted from 
the indicated cell lines and subjected to immunoblotting with antibodies specific to 
Rrm2. Membrane was re-probed for α-tubulin as a loading control. Samples were run 
on a single blot, which was then cropped to remove extraneous lanes. (B) 
Accumulated population doublings (PDL) of 3T3 cells overexpressing Rrm2, Rrm2-
Y177F, Rrm2-Y370F or empty plasmid vector. Cells were cultured following a 3T3 
culture schedule as described in Material and Methods. Plot shows the number of 
PDL. (C) Intracellular ROS levels in 3T3 cells overexpressing Rrm2, Rrm2-Y177F, 
Rrm2-Y370F or empty plasmid vector assessed by FACs analysis of CH3-DCFDA 
fluorescence. Each data point is mean of three independent experiments with error 
bars representing the standard deviations. * Statistically significant difference (p< 
0.05) relative to control vector cells by student t –test. # p=0.08; § p=0.09. 
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3.5. Discussion 
RNR overexpression is common in human cancers. However, up-regulation of 
RNR has long been thought of to act passively as a very downstream target of 
transforming pathway by solely providing dNTPs for cancer cell hyper-proliferation.  
Although deregulation of RNR has been shown to promote genetic instability in yeast 
and cell culture models (Caras and Martin, 1988; Chabes et al., 2003a; Reichard et al., 
2000), the role of RNR deregulation in cancer initiation and progression in mouse 
models and human cancers had not been explored.  We recently extended the analysis 
of RNR deregulation in transgenic mouse models and identified a novel oncogenic 
activity of RNR in lung specific tumorigenesis (Xu et al., 2008). We found that 
broadly overexpressing the small RNR subunits, Rrm2 and p53R2, specifically causes 
lung carcinogenesis through a mutagenic mechanism. The key question we addressed 
in this study is what is the molecular mechanism of RNR-induced mutagenesis and 
lung tumorigenesis.  Here we showed that RNR-induced mutagenesis and lung 
tumorigenesis were neither associated with detectable alterations in dNTP pool 
size/ratios, nor direct transforming activity. Interestingly, Rrm2 overexpressing cells 
exhibited significantly elevated ROS levels . Moreover, cells overexpressing mutant 
Rrm2 proteins, defective for RNR enzyme activity, exhibited enhanced mutagenesis 
and elevated ROS generation. Our results establish the causative role of RNR 
deregulation in elevated ROS production and enhanced mutagenesis, implying that 
free radical generation by RNR is sufficient for mutagenesis, which may be 
independent of RNR enzyme activity.  
Although both p53R2 and Rrm2 have radical production activity, one in vitro 
study showed that p53R2 recombinant protein had anti-oxidant property (Xue et al., 
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2006). It is possible that, unlike Rrm2, p53R2 might drive lung tumor development 
through a different unknown mechanism rather than oxidative stress, or p53R2 
protein also produce free radical in vivo and drives lung tumorigenesis through 
oxidative stress. Mutagenic and carcinogenic analysis of p53R2 mutants that are 
defective for RNR enzyme activity or radical production activity will provide more 
insight into the role of oxidative stress in p53R2-induced lung tumorigenesis. 
It is well known that free radicals let loose in the cell can cause oxidative 
damage to DNA, protein and lipids. RNR has long been conceived of an oxidant-
generating enzyme, along with cytochrome c oxidase, NADPH oxidase and the 
cytochrome P450 system (O'Donnell et al., 1995). However, there is very little 
evidence directly demonstrating the oxidizing ability of RNR protein as an organic 
radical protein. One study reported that recombinant human RRM2 protein generated 
ROS in vitro in a cell free system, although recombinant p53R2 protein has been 
suggested to have antioxidant activity in vitro (Xue et al., 2006). Structural analysis of 
mouse Rrm2 protein showed that a hydrophobic channel to radical site in mouse 
Rrm2 is wider and makes the radical much more accessible to environment than 
E.Coli Rrm2 (Kauppi et al., 1996). Therefore, overexpression of mouse Rrm2 protein 
more likely cause increase oxidative stress due to the more accessible radicals. In our 
study, we provided the first direct evidence that overproduced ROS, probably at least 
partially due to overproduced free radicals in the R2 subunit of RNR, correlated with 
the enhanced mutagenesis caused by RNR overexpression. Since abundant evidence 
suggest that ROS plays an causative role in both human and mouse lung cancer 
development (Inoue et al., 1998; Le Marchand et al., 2002; Minowa et al., 2000; 
Sakumi et al., 2003; Tsuzuki et al., 2001; Xie et al., 2004), elevated ROS production 
and resultant enhanced mutagenesis due to RNR overexpression may explain why 
RNR transgenic mice, with widespread overexpression of RNR, specifically 
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developed lung but not other neoplasms at high frequency. The multiplicative 
increase in mutagenesis and lung carcinogenesis when combining RNR 
overexpression with mismatch repair deficiency also support increased ROS 
production as possible mechanisms since the mismatch repair system can suppresses 
the mutation accumulation due to oxidative DNA damage (Modrich, 2006; Slupphaug 
et al., 2003). ROS also have mitogenic effects on the cells and can play a direct role in 
neoplastic transformation (Irani et al., 1997). Cultured 3T3 cells overexpressing 
Mox1, a superoxide-generating oxidase, have transforming activity, exhibiting 
anchorage-independent growth and tumor formation in athymic mice (Suh et al., 
1999).  
To confirm that increased ROS production by overexpression of Rrm2 
accounts for lung tumorigenesis, we are currently testing the effect of anti-oxidant 
treatment on Rrm2-induced lung tumorigenesis. N-acetylcysteine (NAC) is an 
aminothiol and synthetic precursor of intracellular cysteine and glutathione (GSH) 
and able to detoxify reactive free radicals through conjugation or reduction reaction. 
Anti-oxidant activity of NAC has been proposed to have antimutagenic and 
anticarcinogenic function (van Zandwijk, 1995). NAC has emerged as a most 
promising cancer chemopreventive agents, although 2-year supplement of NAC in 
lung cancer patients resulted in no benefit in terms of survival in clinic trials for NAC 
cancer prevention (van Zandwijk et al., 2000), which may be due to short period NAC 
intervention. In animal models, oral administration of NAC through diet has been 
found to prevent lung adenoma by carcinogens (De Flora et al., 1986).  Our previous 
data showed that 100% of Msh6-/-Rrm2Tg mice develop spontaneous lung neoplasms 
by 6 months of age. A mouse cohort consisting of Msh6-/-Rrm2Tg mice and littermate 
controls are being established and treated with the anti-oxidant NAC in drinking 
water from the date of weaning to 6 months of age. This cohort will then be sacrificed 
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to assess whether NAC alleviates Rrm2-induced lung tumorigenesis. If NAC 
treatment can specifically reduce the lung tumor frequency, size and malignancy 
caused by Rrm2 overexpression, these data will further strengthen the role of ROS 
production by the Rrm2 subunit in RNR-induced lung tumorigenesis. In addition,  the 
role of ROS in RNR-induced lung tumorigenesis can also be confirmed by evaluating 
whether deficiency in base excision repair genes,Ogg1 or Mth1, will accelerate RNR-
induced lung tumor development by crossing RNR transgenic mice to Ogg1 or Mth1 
knockout mice. 
Whether free radical production is required for RNR-induced mutagenesis was 
not elucidated prior to our study. One assumption is that RNR overproduction leads to 
elevated dNTP pools, and this imbalance in dNTP pools accounts for RNR-induced 
mutagenesis. However, there is no convincing evidence for elevated dNTP pools 
caused by over-produced RNR enzyme in mammalian systems. Here we employed 
mutant Rrm2 proteins that have defective RNR enzyme activity to dissect the 
molecular mechanisms of RNR-induced mutagenesis and to distinguish the role of 
RNR enzyme activity and radical production activity in RNR-induced mutagenesis. 
Interestingly, cells overexpressing these mutants still exhibited a mutator phenotype, 
indicating that RNR induced mutagenesis is independent of RNR enzyme activity. 
Our observations imply that RNR overexpression drives lung specific tumorigenesis 
via increased ROS production and oxidative DNA damage, rather than via increased 
RNR enzyme activity. Consistent with this interpretation, mice overexpressing Rrm1-
D57N, a mutant defective for dATP feedback inhibition and exhibiting hyperactive 
RNR enzyme activity, did not show obvious lung tumor predisposition as we 
observed in Rrm2 and p53R2 transgenic mice (Page JL and Weiss RS, unpublished 
data). These data support that RNR deregulation induces lung specific tumorigenesis 
independent of RNR enzyme activity and instead through increased free radical 
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production by overexpression of the small R2 subunit. Increased ROS levels in cells 
overexpressing wildtype Rrm2 and Rrm2-Y177W, Rrm2-Y370W and Rrm2-Y370F 
mutants provide more direct evidence for this hypothesis. Further analysis of lung 
tumor development in transgenic mice overexpressing these Rrm2 mutants would 
confirm whether ROS-induced mutagenesis is responsible for lung carcinogenesis.  
Surprisingly, cells overexpressing Rrm2-Y177F, which is defective for both 
RNR enzyme activity and tyrosyl radical production, still exhibited elevated ROS 
production. One possibility is that Rrm2-Y177F has a dominant negative effect 
through binding to the Rrm1 subunit to inhibit Rrm1 function. There is mounting 
evidence that Rrm1 and p53R2 form a complex to provide dNTPs for maintaining 
mitochondrial genome stability. Deficiency in p532R2 gene has been shown to cause 
severe mitochondrial DNA depletion in muscle (Bourdon et al., 2007). Thus, 
overexpressing Rrm2-Y177F may indirectly inhibit p53R2 function by competing 
with Rrm1 protein, causing mitochondrial dysfunction and a respiratory chain defect, 
and increased ROS production, which also raises the possibility that the Rrm2 
mutants that still can produce radicals but are defective for RNR enzyme activity 
might also have similar dominant negative effect. Analysis of mitochondrial function 
in Rrm2-Y177F mutant by Mitotracker (a probe specifically labeling mitochondria) 
staining, would clarify whether such a dominant negative mechanism occurs. The C-
terminus of Rrm2 is involved in the binding of the R1 subunit (Nordlund and Eklund, 
1993; Uppsten et al., 2006). Rrm2 mutants that are defective for both radical 
production and Rrm1 binding would circumvent this dominant negative effect.  
The effect of RNR over-production on dNTP pool size in mammalian cells 
remains controversial. Various hydroxyurea-resistant cell lines containing a high level 
of overproduced R2 subunits exhibited no or only a modest increase in RNR activity 
and dNTP pools (Lin et al., 2007). In our study, we did not observe altered dNTP pool 
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size or ratios in RNR overexpressing 3T3 cells and RNR transgenic lung cells.   These 
data support that mammalian cells have more strict dATP allosteric inhibition, which 
may be the major control of dNTP pool size. Therefore, overexpression of the small 
subunit of RNR may not lead to increased RNR enzyme activity due to feedback 
inhibition caused by increased dATP levels. However, we cannot rule out the 
possibility of a localized increase in dNTP pools due to subcellular dNTP 
compartmentalization, which is undetectable using currently available dNTP 
measurements. Moreover, other mechanisms, such as the control of other enzymes 
involved in de novo dNTP biosynthesis and the control of the salvage pathway of 
dNTP biosynthesis, may also play a role in keeping dNTP levels undisturbed in RNR 
overexpressing cells.  
It has been proposed that Rrm2 has transforming activity based on the 
experiments showing that Rrm2 can cooperate with a variety of oncogenes to promote 
focus formation, anchorage-independent growth and tumor formation in syngeneic 
mice (Fan et al., 1998; Fan et al., 1996). In our study, we did not observe the 
enhanced focus formation when we co-transfected Rrm2 with H-ras into 3T3 cells. 
This discrepancy may be due to different Rrm2 expressing constructs and different 
transformation methods; in our study, we used pCaggs expression constructs that 
place Rrm2 under the chicken β-actin promoter and cytomegalovirus enhancer 
regulatory sequence to get high levels of expression. We co-transfected H-ras with 
individual RNR genes, or vector (negative control) and c-Myc (positive control) into 
3T3 cells. Previous studies used retrovirus expression constructs to overexpress Rrm2 
and then transfected H-ras into established Rrm2 expressing cells. Our results suggest 
that Rrm2 expressed from the pCaggs construct, cannot enhance H-ras induced focus 
formation. Thus, acute transforming activity probably does not account for RNR-
induced mutagenesis and lung tumorigenesis.  
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Our findings not only elucidate the involvement of ROS production in Rrm2-
induced mutagenesis, and potentially lung carcinogenesis, but also might have 
implications in the response of cancers to chemotherapeutic reagents. Inhibitors of 
Rrm2, such as hydroxyurea, have long been used as effective anti-cancer 
chemotherapy treatment. The molecular mechanism of hydroxyurea was identified 
long after its application; it has been thought to inhibit RNR enzyme activity through 
inactivation of the small R2 subunit by destruction of the tyrosyl free radical. Our 
findings suggest that anti-cancer effect of hydroxyurea might not be limited to the 
anti-proliferative effect of RNR inhibition, but may also be due to the inhibition of 
intracellular ROS production.  
 
 
 
116 
CHAPTER 4 
 
  Summary and Future Directions  
 
RNR plays an essential role in maintaining genomic stability by providing 
dNTPs, the basic building blocks of the genome, for DNA replication and repair. 
Abnormal expression of RNR has long been linked to human cancers, and studies in 
yeast and cultured cells show that deregulation of RNR is mutagenic. However the 
physiological effects of RNR deregulation in mammals have not been fully explored. 
The aim of this dissertation was to elucidate the physiological effect of RNR 
deregulation using transgenic mouse models (chapter 2) and to further dissect the 
molecular mechanisms of RNR-induced mutagenesis and lung tumorigenesis (chapter 
3). 
 To determine the consequence of RNR deregulation in an animal model, we 
generated Rrm1, Rrm2 and p53R2 transgenic mice and obtained widespread, high 
level overexpression of the small RNR subunits, Rrm2 and p53R2, and the restricted 
overexpression of the large RNR subunit Rrm1 in transgenic mice. Notably, 
widespread overexpression of either small RNR subunit in mice specifically promotes 
lung tumorigenesis, with Rrm2 being more potent than p53R2 with respect to tumor 
size, multiplicity and malignancy. The lung neoplasms in Rrm2Tg and p53R2Tg mice 
histopathologically and immunohistochemically mimic human lung cancer, 
particularly lung adenocarcinomas. These finding raise the possibility that increased 
RNR expression may have a role in human lung tumorigenesis. 
To investigate the mechanism by which RNR deregulation causes lung 
tumorigenesis, we generated RNR overexpressing 3T3 cells and found that RNR 
overexpression is mutagenic in cultured cells. To evaluate a role for mutagenesis in 
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RNR-induced lung carcinogenesis, we investigated whether combining RNR 
deregulation with a defect in the mismatch repair system would synergistically 
increase mutagenesis and tumorigenesis.  We found that mismatch repair deficiency 
synergized with RNR overexpression to greatly increase mutagenesis and 
carcinogenesis. Our data support that mismatch repair normally suppresses the 
mutations induced by RNR de-regulation and further confirmed that RNR-induced 
lung tumorigenesis through a mutagenic mechanism.  
A mutagenic mechanism implies that RNR overexpression triggers mutation 
accumulations in oncogenes or tumor suppressor genes, driving lung tumorigenesis. 
K-ras is frequently mutated in both human lung cancers and mouse lung cancers. We 
explored whether activating mutations of K-ras is involved in RNR-induced lung 
tumorigenesis and found that mutated K-ras is central to Rrm2- and p53R2-induced 
lung tumorigenesis.  
A key question from this study is what is the molecular mechanism for 
mutagenesis and lung tumorigenesis induced by Rrm2 and p53R2 overexpression. One 
possibility is that RNR overexpression leads to altered dNTP levels that impair 
replication fidelity and trigger mutations in growth regulatory genes. A second 
possibility is that the small RNR subunit has direct transforming activity, driving lung 
tumorigenesis. Alternatively, free radical production by Rrm2 or p53R2 contributes to 
cell transformation through oxidative stress induced mutagenesis. Thus, we propose 
the initial model for lung tumorigenesis by RNR overexpression based on our findings 
in chapter 2 (Fig. 4.1). This model postulates that overexpression of the small RNR 
subunit leads to mutagenesis, through either altered dNTP levels and/or increased 
oxidative stress due to overproduced free radicals. The mutagenic effect of RNR 
overexpression results in mutations in growth regulatory genes, such as K-ras, driving 
lung neoplasm initiation  
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Figure 4.1.  Initial model for RNR overexpression and lung cancer. Overexpression of 
the small RNR subunit leads to mutagenesis through either altered dNTP levels and/or 
increased oxidative stress due to overproduced free radicals. The mutagenic effect of 
RNR overexpression results in mutations in growth regulatory genes, such as K-ras, 
driving lung neoplasm initiation and /or progression. Alternatively, the small RNR 
subunit has direct transforming activity to transform normal lung cells into malignant 
cancer cells. 
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and /or progression. Alternatively, the small RNR subunit could have direct 
transforming activity through an unknown mechanism to transform normal lung cells 
into malignant cancer cells. 
In chapter 3, we performed a series of experiments to address whether altered 
dNTP levels, RNR transforming activity, or increased oxidative stress are involved in 
RNR-induced mutagenesis and lung tumorigenesis.  
RNR overexpression was not associated with detectable changes in dNTP 
levels or ratios in RNR overexpressing 3T3 cells and transgenic lung tissue, 
suggesting that RNR overexpression-induced mutagenesis and lung tumorigenesis 
might be not involved in altered dNTP levels or ratios. Moreover, RNR did not show 
direct transforming activity, nor enhanced transforming activity when co-transfected 
with H-ras, suggesting that RNR induced mutagenesis and lung carcinogenesis might 
not involve the direct transforming activity of RNR. 
To determine whether radical production activity is involved in RNR-induced 
mutagenesis, we generated two Rrm2 mutant cell pools. The Rrm2-Y177W mutant, 
with a mutation at the tyrosyl radical site, has been shown to be defective for enzyme 
activity and to only produce a transient tryptophan radical. The Rrm2-Y370W mutant, 
with a mutations in the radical transfer path between Rrm2 and Rrm1 subunits, only 
has 1.7% of RNR enzyme activity compared to the wildtype Rrm2 protein. Both 
mutants are defective for RNR enzyme activity, but can still produce a transient 
tryptophan radical or the initial tyrosyl radical, respectively. Interestingly, cells 
overexpressing either mutant still exhibited enhanced mutagenesis, suggesting that 
Rrm2-induced mutagenesis likely is independent of RNR enzyme activity, but rather 
depends on its radical production activity. 
Rrm2 overexpressing cells showed significantly higher intracellular ROS 
levels than control cells. Moreover, cells overexpressing Rrm2 mutants, also showed 
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increased ROS levels in agreement with their enhanced mutagenesis. Although it is 
possible that these Rrm2 mutants, which are able to produce radical but defective for 
RNR enzyme activity, also have dominant negative effect and cause mitochondrial 
defects and associated oxidative stress, these results highlight the importance of 
radical production, rather than RNR enzyme activity, as the major driving force of 
RNR induced mutagenesis, and potentially lung tumorigenesis.  
Based on these findings, I propose a model for RNR-induced lung 
tumorigenesis as shown in Fig. 4.2. Overexpression of the small RNR subunit leads to 
mutagenesis through increased oxidative stress, likely due to overproduction of free 
radicals. The mutagenic effect of RNR overexpression results in mutations in growth 
regulatory genes, such as K-ras, driving lung neoplasm formation. 
Ongoing experiments, testing whether anti-oxidant treatment will alleviate 
Rrm2-induced lung tumorigenesis in a mouse model, will further strengthen the role 
of oxidative stress in RNR-induced mutagenesis and lung tumorigenesis. In addition, 
analysis of mutations in p53R2 radical production site and radical transfer sites would 
provide more information about the role of the radical property of the small RNR 
subunit in mutagenesis and tumorigenesis. p53R2 shares 80% homology with Rrm2. 
The dinuclear iron center, the tyrosyl radical site, and the radical transfer pathway are 
all conserved between Rrm2 and p53R2. However, recombinant p53R2 protein has 
been suggested to have anti-oxidant activity in vitro (Xue et al., 2006).Analysis of 
similar mutants at tyrosyl radical site and radical transfer pathway of p53R2 would 
confirm that Rrm2 and p53R2 utilize the same mutagenic mechanism, such as 
increased ROS production by overproduced free radicals. Finally, analysis of whether 
repair of oxidative DNA damage by the base excision repair pathway suppresses RNR 
induced lung tumorigenesis by crossing RNR transgenic mice to mice defective for  
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Figure 4.2.  Current model for mechanisms of RNR overexpression and lung cancer. 
Overexpression of the small RNR subunit leads to mutagenesis through increase 
oxidative stress, possibly due to overproduced free radicals, and thereby enhanced 
mutagenesis. The mutagenic effect of RNR overexpression results in mutations in 
growth regulatory genes, such as K-ras, driving lung neoplasm formation. 
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repairing oxidative DNA damage would establish the significance of oxidative DNA 
damage in RNR-induced lung tumorigenesis.  
This novel lung cancer model based on RNR overexpression holds great 
promise for further dissection of the molecular mechanisms of lung cancer initiation 
and progression. Interesting questions that can be addressed using this novel lung 
cancer model in future studies include 1) Are bronchioalveolar stem cells (BASCs), 
the putative lung cancer stem cells, more sensitive to RNR-induced mutagenesis and 
does BASCs expansion occur during early stage of RNR-induced lung tumorigenesis? 
To address this question, BASCs can be isolated from RNR transgenic mice at 
different development stage and mutation frequency of RNR overexpression BASCs 
cells can be measured using Hprt assay. 2) What are the other growth regulatory 
genes in addition to K-ras that are mutated and involved in RNR-induced lung 
tumors? Genetic alterations of other growth regulatory genes can be identified by 
sequence capture microarray analysis in RNR-induced lung tumors. 3) Are alterations 
in RRM2 and p53R2 genes (mutations or gene amplification) involved in human lung 
carcinogenesis? This question can be addressed by sequencing and in situ 
hybridization of human RRM2 and p53R2 genes in human lung cancer samples.  
Aside from dissecting the mechanisms of lung cancer development, this novel 
mouse lung cancer model also can be used to test putative chemopreventive or 
chemotherapeutic agents in lung cancer prevention and treatment. It also has value as 
a model of lung cancer for imaging studies for micro-CT and multiphoton 
microscope, such as for computational assessment of lung tumor growth rate, tumor 
progression, and regression using micro-CT technology.  
- 
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